data_1g1z_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1g1z _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 . . . . . 0 N--CA 1.448 -0.537 0 CA-C-O 121.223 0.535 . . . . 0.0 112.162 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m . . . . . 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm . . . . . 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 . . . . . 0 CA--C 1.502 -0.866 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p . . . . . 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 . . . . . 0 CA--C 1.5 -0.978 0 CA-C-O 120.777 0.323 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p . . . . . 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m . . . . . 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p . . . . . 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt . . . . . 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 . . . . . 0 CA--C 1.5 -0.952 0 CA-C-O 121.075 0.464 . . . . 0.0 111.633 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m . . . . . 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 . . . . . 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm . . . . . 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.442 -0.83 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m . . . . . 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 . . . . . 0 CA--C 1.505 -0.762 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p . . . . . 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m . . . . . 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt . . . . . 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 . . . . . 0 CA--C 1.505 -0.768 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 . . . . . 0 CA--C 1.505 -0.759 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm . . . . . 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m . . . . . 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 . . . . . 0 N--CA 1.442 -0.835 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm . . . . . 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 CA--C 1.502 -0.869 0 CA-C-O 120.513 0.197 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m . . . . . 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 . . . . . 0 CA--C 1.501 -0.924 0 CA-C-O 121.118 0.485 . . . . 0.0 111.516 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m . . . . . 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 . . . . . 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp . . . . . 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 . . . . . 0 N--CA 1.443 -0.797 0 CA-C-O 120.682 0.277 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p . . . . . 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 . . . . . 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p . . . . . 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm . . . . . 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 CA--C 1.503 -0.834 0 CA-C-O 120.764 0.316 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m . . . . . 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm . . . . . 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m . . . . . 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp . . . . . 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 . . . . . 0 N--CA 1.44 -0.938 0 CA-C-O 121.131 0.491 . . . . 0.0 111.94 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m . . . . . 0 N--CA 1.432 -1.37 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p . . . . . 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 . . . . . 0 CA--C 1.5 -0.966 0 CA-C-O 121.667 0.746 . . . . 0.0 112.346 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p . . . . . 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m . . . . . 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.404 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.404 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 38.8 t70 . . . . . 0 N--CA 1.494 1.748 0 N-CA-C 102.974 -2.973 . . . . 0.0 102.974 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -172.67 -170.68 0.71 Allowed 'General case' 0 N--CA 1.43 -1.442 1 N-CA-C 97.104 -5.147 . . . . 0.0 97.104 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p -105.74 172.38 6.83 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 172.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -82.71 141.62 32.28 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 66.5 23.22 10.51 Favored 'General case' 0 C--N 1.357 0.933 0 C-N-CA 125.898 1.679 . . . . 0.0 112.162 -172.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -111.21 -123.31 0.27 Allowed 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.6 p -153.96 -160.2 1.07 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 102.754 -3.054 . . . . 0.0 102.754 173.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.7 mt -148.99 165.05 18.68 Favored Pre-proline 0 N--CA 1.43 -1.469 1 N-CA-C 97.491 -5.003 . . . . 0.0 97.491 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -64.01 144.5 55.77 Favored 'Cis proline' 0 CA--C 1.504 -0.986 0 CA-C-N 124.088 2.496 . . . . 0.0 109.74 -6.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -107.45 108.61 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.304 0 N-CA-C 105.372 -2.084 . . . . 0.0 105.372 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.2 mp -137.45 -63.13 0.6 Allowed 'General case' 0 CA--C 1.487 -1.448 1 N-CA-C 99.447 -4.279 . . . . 0.0 99.447 162.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.2 tmtm? -112.41 148.0 35.25 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 95.579 -5.711 . . . . 0.0 95.579 161.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -162.05 -166.66 1.47 Allowed 'General case' 0 N--CA 1.431 -1.408 1 N-CA-C 97.758 -4.904 . . . . 0.0 97.758 177.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -74.46 131.47 13.24 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 105.849 -2.9 . . . . 0.0 105.849 173.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -88.33 133.45 34.07 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -159.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m -90.36 150.88 21.7 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -138.09 161.76 35.94 Favored 'General case' 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 62.3 mt -153.59 167.59 29.03 Favored 'General case' 0 N--CA 1.424 -1.754 1 N-CA-C 94.934 -5.95 . . . . 0.0 94.934 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.955 0 O-C-N 124.225 0.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.495 1.796 0 N-CA-C 102.041 -3.318 . . . . 0.0 102.041 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -143.61 159.09 43.08 Favored 'General case' 0 N--CA 1.427 -1.601 1 N-CA-C 95.389 -5.782 . . . . 0.0 95.389 175.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p -176.46 -177.88 0.88 Allowed 'General case' 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 -178.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -75.29 140.35 43.08 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 64.39 30.19 13.26 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 127.933 2.493 . . . . 0.0 112.675 -171.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p -120.46 -18.02 7.98 Favored 'General case' 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -74.09 -69.8 0.42 Allowed 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -160.14 164.39 19.95 Favored Pre-proline 0 N--CA 1.421 -1.898 1 N-CA-C 97.704 -4.925 . . . . 0.0 97.704 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -68.09 167.06 65.46 Favored 'Cis proline' 0 CA--C 1.5 -1.184 0 CA-C-N 124.683 2.708 . . . . 0.0 110.459 -1.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.3 tp -75.44 97.18 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.184 0 CA-C-O 122.371 1.082 . . . . 0.0 108.09 178.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -109.56 -53.68 2.63 Favored 'General case' 0 CA--C 1.483 -1.634 0 N-CA-C 102.527 -3.138 . . . . 0.0 102.527 163.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -138.63 160.9 38.48 Favored 'General case' 0 N--CA 1.418 -2.074 1 N-CA-C 94.906 -5.961 . . . . 0.0 94.906 153.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -123.19 145.49 48.59 Favored 'General case' 0 CA--C 1.492 -1.275 1 N-CA-C 97.966 -4.827 . . . . 0.0 97.966 168.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.15 -134.75 9.95 Favored Glycine 0 C--N 1.35 1.352 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 169.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 45.3 tp -73.57 127.88 33.95 Favored 'General case' 0 C--N 1.36 1.056 0 C-N-CA 125.815 1.646 . . . . 0.0 113.036 -159.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m -90.26 148.01 23.17 Favored 'General case' 0 CA--C 1.493 -1.24 0 C-N-CA 124.738 1.215 . . . . 0.0 108.407 174.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -139.72 171.01 14.85 Favored 'General case' 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.8 mt -147.71 156.24 42.55 Favored 'General case' 0 N--CA 1.422 -1.833 1 N-CA-C 93.89 -6.337 . . . . 0.0 93.89 173.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.838 0 O-C-N 124.507 1.129 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 N--CA 1.487 1.386 0 N-CA-C 102.585 -3.117 . . . . 0.0 102.585 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 61.9 t0 -97.29 -71.99 0.66 Allowed 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 104.816 -2.29 . . . . 0.0 104.816 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p -146.73 172.43 13.64 Favored 'General case' 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 173.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -86.39 135.88 33.34 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 79.69 1.78 2.17 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 127.119 2.168 . . . . 0.0 110.463 -176.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p -99.51 91.67 5.02 Favored 'General case' 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.02 162.08 25.06 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 175.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 96.4 mt -137.46 159.99 67.16 Favored Pre-proline 0 N--CA 1.435 -1.179 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 170.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -64.65 148.66 71.43 Favored 'Cis proline' 0 CA--C 1.506 -0.913 0 CA-C-N 126.78 3.457 . . . . 0.0 114.224 14.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.9 tt -72.1 -24.45 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 C-N-CA 125.553 1.541 . . . . 0.0 110.863 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 70.4 mt -75.03 -32.5 61.6 Favored 'General case' 0 CA--C 1.5 -0.953 0 O-C-N 121.38 -0.825 . . . . 0.0 109.979 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmtp -82.9 -53.0 6.19 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.4 m-80 -89.57 -109.63 0.08 Allowed 'General case' 0 N--CA 1.442 -0.826 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 -170.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 166.16 -151.89 20.62 Favored Glycine 0 CA--C 1.474 -2.502 1 N-CA-C 99.303 -5.519 . . . . 0.0 99.303 175.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 82.2 mt -113.76 177.45 4.63 Favored 'General case' 0 N--CA 1.432 -1.341 0 N-CA-C 102.182 -3.266 . . . . 0.0 102.182 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m -89.06 141.61 28.35 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 -176.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -142.54 170.25 16.05 Favored 'General case' 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.9 mt -147.77 167.82 23.72 Favored 'General case' 0 N--CA 1.423 -1.808 1 N-CA-C 94.345 -6.169 . . . . 0.0 94.345 174.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.869 0 O-C-N 124.351 1.032 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 . . . . . 0 N--CA 1.505 2.296 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -82.89 -170.15 2.86 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 151.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.39 -169.26 3.31 Favored 'General case' 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 178.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -81.66 140.98 34.05 Favored 'General case' 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 64.12 28.1 14.13 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 126.184 1.794 . . . . 0.0 111.633 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -119.95 123.43 43.51 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -133.58 159.19 41.19 Favored 'General case' 0 N--CA 1.431 -1.398 1 N-CA-C 94.649 -6.056 . . . . 0.0 94.649 161.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 pp -155.42 160.76 30.6 Favored Pre-proline 0 N--CA 1.425 -1.677 0 N-CA-C 101.124 -3.658 . . . . 0.0 101.124 178.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.66 167.87 72.39 Favored 'Cis proline' 0 N--CA 1.453 -0.887 0 N-CA-C 108.92 -1.223 . . . . 0.0 108.92 -23.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tt -150.03 -46.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 N-CA-C 102.502 -3.147 . . . . 0.0 102.502 178.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 86.7 mt -117.33 -151.73 0.49 Allowed 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 101.726 -3.435 . . . . 0.0 101.726 167.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.4 mptp? -91.81 59.96 3.8 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 170.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -83.84 -122.71 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 124.921 1.288 . . . . 0.0 108.579 -177.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 150.67 -144.15 11.48 Favored Glycine 0 CA--C 1.475 -2.439 1 N-CA-C 98.677 -5.769 . . . . 0.0 98.677 -174.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.7 mt -84.64 -167.09 1.66 Allowed 'General case' 0 N--CA 1.438 -1.061 0 O-C-N 125.116 1.127 . . . . 0.0 108.435 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m -90.39 150.29 21.92 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -173.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -109.98 -179.61 3.84 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 tp -162.1 164.34 28.1 Favored 'General case' 0 N--CA 1.421 -1.894 1 N-CA-C 96.111 -5.515 . . . . 0.0 96.111 -177.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.027 0 O-C-N 124.226 0.954 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 101.881 -3.377 . . . . 0.0 101.881 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.96 -24.77 59.68 Favored 'General case' 0 C--N 1.352 0.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.26 176.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -138.81 -167.86 2.29 Favored 'General case' 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 173.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -73.69 143.2 46.3 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 65.67 27.98 11.23 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.69 1.996 . . . . 0.0 112.153 -173.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p -113.83 151.93 31.4 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.91 159.68 21.26 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 165.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 16.0 mt -156.67 165.15 19.36 Favored Pre-proline 0 N--CA 1.434 -1.25 1 N-CA-C 97.668 -4.938 . . . . 0.0 97.668 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -69.72 -77.24 0.0 OUTLIER 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 125.13 2.868 . . . . 0.0 110.988 -2.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tp -129.0 121.33 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.741 1 N-CA-C 97.583 -4.969 . . . . 0.0 97.583 167.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.6 mt -140.44 -98.19 0.15 Allowed 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -129.23 130.38 46.19 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 96.512 -5.366 . . . . 0.0 96.512 157.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 177.19 -173.35 0.11 Allowed 'General case' 0 N--CA 1.426 -1.671 1 N-CA-C 97.209 -5.108 . . . . 0.0 97.209 -168.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.69 -170.53 42.94 Favored Glycine 0 N--CA 1.424 -2.166 1 N-CA-C 97.314 -6.314 . . . . 0.0 97.314 -177.349 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.13 172.13 12.99 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 177.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m -90.29 163.4 14.77 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 175.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -141.4 174.53 10.46 Favored 'General case' 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -83.59 71.93 10.33 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.167 0 CA-C-N 116.383 -0.371 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -89.8 -165.35 1.33 Allowed 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 103.822 -2.658 . . . . 0.0 103.822 157.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -151.91 -176.07 5.49 Favored 'General case' 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -78.76 144.45 35.18 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 70.82 18.58 6.12 Favored 'General case' 0 C--N 1.356 0.865 0 C-N-CA 126.572 1.949 . . . . 0.0 112.397 -175.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p -106.14 164.69 11.79 Favored 'General case' 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.8 p -164.09 -125.24 0.02 OUTLIER 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 -166.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 95.7 mt -155.58 171.1 7.7 Favored Pre-proline 0 N--CA 1.425 -1.687 1 N-CA-C 98.593 -4.595 . . . . 0.0 98.593 -161.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -64.56 135.27 21.38 Favored 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 123.093 2.14 . . . . 0.0 109.922 -16.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.8 pt -73.04 155.73 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.068 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 53.4 mt 79.08 -35.47 0.16 Allowed 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 126.187 1.795 . . . . 0.0 110.717 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -76.39 -62.43 1.62 Allowed 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -133.85 -129.63 0.17 Allowed 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 100.631 -3.84 . . . . 0.0 100.631 173.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 84.52 -58.59 4.98 Favored Glycine 0 CA--C 1.487 -1.676 0 N-CA-C 110.326 -1.11 . . . . 0.0 110.326 168.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 83.2 mt -81.98 149.31 28.22 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m -90.54 151.89 21.15 Favored 'General case' 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.42 173.65 7.02 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.2 mp -84.43 68.2 10.17 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.174 0 CA-C-N 116.499 -0.319 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.497 1.906 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -158.42 179.52 9.06 Favored 'General case' 0 N--CA 1.43 -1.451 1 N-CA-C 96.778 -5.267 . . . . 0.0 96.778 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.34 160.59 34.56 Favored 'General case' 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 168.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -65.87 138.92 58.2 Favored 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 68.12 20.76 8.88 Favored 'General case' 0 C--N 1.355 0.824 0 C-N-CA 125.531 1.532 . . . . 0.0 112.175 -175.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.6 -115.0 0.3 Allowed 'General case' 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.4 p -167.15 -163.3 0.52 Allowed 'General case' 0 N--CA 1.427 -1.599 1 N-CA-C 98.046 -4.798 . . . . 0.0 98.046 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 19.0 mt -150.42 167.76 12.35 Favored Pre-proline 0 N--CA 1.429 -1.496 1 N-CA-C 97.512 -4.996 . . . . 0.0 97.512 176.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -66.99 151.96 83.43 Favored 'Cis proline' 0 CA--C 1.504 -1.004 0 CA-C-N 122.988 2.103 . . . . 0.0 109.992 -9.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.2 tp -99.9 102.05 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 99.4 mt -124.72 -79.08 0.61 Allowed 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 100.659 -3.83 . . . . 0.0 100.659 165.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.7 mttp -132.03 145.33 51.37 Favored 'General case' 0 N--CA 1.424 -1.747 1 N-CA-C 95.213 -5.847 . . . . 0.0 95.213 154.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -160.36 -50.06 0.05 OUTLIER 'General case' 0 CA--C 1.487 -1.467 0 N-CA-C 100.855 -3.757 . . . . 0.0 100.855 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.5 -172.42 13.27 Favored Glycine 0 N--CA 1.427 -1.926 1 N-CA-C 98.6 -5.8 . . . . 0.0 98.6 162.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.4 tp -137.33 131.95 32.91 Favored 'General case' 0 CA--C 1.483 -1.63 1 N-CA-C 99.285 -4.339 . . . . 0.0 99.285 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m -90.71 150.11 21.77 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.13 164.5 30.5 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -85.87 66.91 9.84 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 -173.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.128 0 CA-C-N 116.587 -0.279 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 100.917 -3.734 . . . . 0.0 100.917 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.79 -77.75 0.36 Allowed 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.793 -1.929 . . . . 0.0 105.793 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -140.17 170.76 15.23 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 176.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp -79.5 137.57 37.25 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 70.22 19.88 6.45 Favored 'General case' 0 C--N 1.355 0.837 0 C-N-CA 127.345 2.258 . . . . 0.0 112.585 -174.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p -137.15 170.27 16.38 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -169.21 174.64 6.05 Favored 'General case' 0 N--CA 1.424 -1.751 1 N-CA-C 98.008 -4.812 . . . . 0.0 98.008 -163.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -143.81 162.04 43.13 Favored Pre-proline 0 N--CA 1.433 -1.318 1 N-CA-C 97.841 -4.874 . . . . 0.0 97.841 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -63.07 145.28 53.31 Favored 'Cis proline' 0 CA--C 1.503 -1.049 0 CA-C-N 126.154 3.233 . . . . 0.0 115.328 17.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.3 tt -69.83 149.18 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.941 0 C-N-CA 125.404 1.481 . . . . 0.0 108.195 -174.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 67.5 mt 75.19 -48.58 0.63 Allowed 'General case' 0 C--N 1.356 0.885 0 C-N-CA 127.607 2.363 . . . . 0.0 111.172 178.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -64.69 -44.79 89.16 Favored 'General case' 0 CA--C 1.504 -0.824 0 C-N-CA 125.429 1.491 . . . . 0.0 107.743 177.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -80.5 -70.07 0.55 Allowed 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 166.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.26 -143.49 8.6 Favored Glycine 0 N--CA 1.422 -2.264 1 N-CA-C 98.706 -5.758 . . . . 0.0 98.706 172.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -152.46 -179.63 7.74 Favored 'General case' 0 N--CA 1.426 -1.661 1 N-CA-C 95.255 -5.831 . . . . 0.0 95.255 161.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m -89.47 143.88 26.47 Favored 'General case' 0 CA--C 1.489 -1.372 0 CA-C-N 120.439 1.472 . . . . 0.0 107.388 -173.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -124.88 -163.59 1.2 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.6 tp -135.02 143.16 46.62 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 94.357 -6.164 . . . . 0.0 94.357 172.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.271 0.982 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.1 m-20 . . . . . 0 N--CA 1.498 1.968 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -148.38 161.76 40.94 Favored 'General case' 0 N--CA 1.431 -1.404 1 N-CA-C 94.961 -5.94 . . . . 0.0 94.961 171.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p -153.51 163.75 39.41 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 -178.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -74.89 143.97 43.56 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 70.3 22.55 5.37 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 126.487 1.915 . . . . 0.0 113.003 -176.096 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p -107.03 176.59 5.12 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.7 p -151.04 168.21 25.31 Favored 'General case' 0 N--CA 1.419 -1.983 1 N-CA-C 98.765 -4.532 . . . . 0.0 98.765 -173.386 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 92.3 mt -144.12 157.16 57.62 Favored Pre-proline 0 N--CA 1.425 -1.722 1 N-CA-C 95.497 -5.742 . . . . 0.0 95.497 175.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.13 164.22 74.68 Favored 'Cis proline' 0 CA--C 1.503 -1.05 0 CA-C-N 124.764 2.737 . . . . 0.0 110.582 5.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -85.36 119.48 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.3 mt -137.0 -77.09 0.41 Allowed 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 103.902 -2.629 . . . . 0.0 103.902 174.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 mtpt -134.12 47.5 2.41 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 -178.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 176.91 175.41 0.37 Allowed 'General case' 0 N--CA 1.427 -1.615 1 N-CA-C 96.465 -5.383 . . . . 0.0 96.465 -164.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.04 -51.53 0.69 Allowed Glycine 0 CA--C 1.484 -1.89 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 173.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.0 mt -80.63 130.95 35.41 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m -90.7 147.15 23.45 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 167.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -143.85 156.35 44.43 Favored 'General case' 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.8 mt -155.63 163.89 39.33 Favored 'General case' 0 N--CA 1.423 -1.777 1 N-CA-C 94.554 -6.091 . . . . 0.0 94.554 176.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.234 0.959 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.6 t70 69.66 -103.69 0.05 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 125.557 1.543 . . . . 0.0 108.402 -175.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p -134.4 168.43 18.93 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 174.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm -89.78 141.38 28.68 Favored 'General case' 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 65.32 25.98 12.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 C-N-CA 127.431 2.292 . . . . 0.0 112.891 -174.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -146.61 -177.65 5.75 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 p -167.44 176.91 6.29 Favored 'General case' 0 N--CA 1.417 -2.096 1 N-CA-C 99.874 -4.121 . . . . 0.0 99.874 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -139.89 157.72 69.0 Favored Pre-proline 0 N--CA 1.424 -1.733 1 N-CA-C 94.366 -6.161 . . . . 0.0 94.366 160.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -68.31 172.54 42.61 Favored 'Cis proline' 0 C--N 1.319 -1.023 0 CA-C-N 124.461 2.629 . . . . 0.0 110.941 -8.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.405 ' H ' HD12 ' A' ' 14' ' ' ILE . 0.0 OUTLIER -77.84 121.59 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 C-N-CA 125.388 1.475 . . . . 0.0 109.626 -170.731 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.92 -64.0 1.29 Allowed 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 103.694 -2.706 . . . . 0.0 103.694 172.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -152.24 42.01 0.65 Allowed 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 103.167 -2.901 . . . . 0.0 103.167 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -90.49 -144.37 0.17 Allowed 'General case' 0 CA--C 1.5 -0.972 0 C-N-CA 125.229 1.412 . . . . 0.0 107.349 -164.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.19 -165.61 38.7 Favored Glycine 0 N--CA 1.421 -2.312 1 N-CA-C 97.218 -6.353 . . . . 0.0 97.218 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -86.45 174.31 9.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 170.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m -90.31 140.3 29.83 Favored 'General case' 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 166.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.63 171.84 11.29 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 23.0 mt -155.08 167.73 29.38 Favored 'General case' 0 N--CA 1.424 -1.737 1 N-CA-C 95.285 -5.82 . . . . 0.0 95.285 -176.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.359 0.994 0 O-C-N 123.894 0.746 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.498 1.945 0 N-CA-C 104.882 -2.266 . . . . 0.0 104.882 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.2 m-20 -154.47 -177.44 6.47 Favored 'General case' 0 N--CA 1.431 -1.383 1 N-CA-C 96.183 -5.488 . . . . 0.0 96.183 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p -161.91 -175.94 4.94 Favored 'General case' 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -76.16 144.06 40.77 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 70.58 20.55 5.77 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 127.753 2.421 . . . . 0.0 111.851 -173.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -137.77 -174.44 3.78 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.95 165.56 33.82 Favored 'General case' 0 N--CA 1.425 -1.679 1 N-CA-C 97.502 -4.999 . . . . 0.0 97.502 179.021 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -168.51 173.57 2.54 Favored Pre-proline 0 N--CA 1.431 -1.398 1 N-CA-C 98.831 -4.507 . . . . 0.0 98.831 -170.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -64.6 -62.25 0.03 OUTLIER 'Cis proline' 0 CA--C 1.498 -1.296 0 CA-C-N 125.753 3.09 . . . . 0.0 108.64 -1.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.346 2.8 mt 42.08 -112.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 C-N-CA 128.694 2.798 . . . . 0.0 112.83 177.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 60.7 mt -134.66 -146.71 0.26 Allowed 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -74.27 10.17 1.37 Allowed 'General case' 0 C--N 1.358 0.937 0 C-N-CA 124.538 1.135 . . . . 0.0 112.989 -173.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -70.84 -26.04 63.1 Favored 'General case' 0 C--N 1.35 0.625 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 163.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.99 29.59 7.91 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 176.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -117.15 104.38 11.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 176.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m -90.81 149.62 21.9 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 172.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.48 155.83 40.27 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -169.62 173.08 6.53 Favored 'General case' 0 N--CA 1.423 -1.819 1 N-CA-C 95.693 -5.669 . . . . 0.0 95.693 173.804 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.89 0 O-C-N 124.203 0.94 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 . . . . . 0 N--CA 1.498 1.974 0 N-CA-C 102.552 -3.129 . . . . 0.0 102.552 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -156.47 166.31 33.79 Favored 'General case' 0 N--CA 1.428 -1.567 1 N-CA-C 95.652 -5.684 . . . . 0.0 95.652 175.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p -168.25 177.87 5.23 Favored 'General case' 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 -177.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -86.96 143.66 27.27 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 76.18 11.89 2.84 Favored 'General case' 0 CA--C 1.502 -0.869 0 C-N-CA 127.015 2.126 . . . . 0.0 111.304 -178.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p -134.36 -157.81 0.83 Allowed 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 p -173.23 -177.13 1.47 Allowed 'General case' 0 N--CA 1.425 -1.703 1 N-CA-C 98.324 -4.695 . . . . 0.0 98.324 -179.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -160.14 165.75 17.13 Favored Pre-proline 0 N--CA 1.428 -1.558 1 N-CA-C 99.111 -4.403 . . . . 0.0 99.111 178.315 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -63.77 -65.42 0.03 OUTLIER 'Cis proline' 0 CA--C 1.503 -1.065 0 CA-C-N 125.702 3.072 . . . . 0.0 111.69 0.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -133.72 132.65 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.678 1 N-CA-C 97.024 -5.176 . . . . 0.0 97.024 167.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.4 mt -167.12 -96.8 0.01 OUTLIER 'General case' 0 N--CA 1.434 -1.264 1 N-CA-C 95.031 -5.914 . . . . 0.0 95.031 -179.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -106.47 97.51 7.3 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 102.994 -2.965 . . . . 0.0 102.994 162.479 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -155.65 178.39 10.3 Favored 'General case' 0 CA--C 1.491 -1.321 1 N-CA-C 97.131 -5.137 . . . . 0.0 97.131 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.84 -84.55 0.11 Allowed Glycine 0 CA--C 1.476 -2.382 1 N-CA-C 101.757 -4.537 . . . . 0.0 101.757 175.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 99.3 mt -139.29 146.06 39.9 Favored 'General case' 0 N--CA 1.419 -1.992 1 N-CA-C 96.677 -5.305 . . . . 0.0 96.677 167.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m -90.95 142.95 27.23 Favored 'General case' 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 151.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -145.57 155.02 42.79 Favored 'General case' 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -171.52 175.82 3.96 Favored 'General case' 0 N--CA 1.424 -1.735 1 N-CA-C 96.012 -5.551 . . . . 0.0 96.012 177.493 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.944 0 O-C-N 124.231 0.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 . . . . . 0 N--CA 1.49 1.553 1 N-CA-C 99.669 -4.197 . . . . 0.0 99.669 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -70.48 -47.76 59.03 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 163.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -96.44 169.97 9.55 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 173.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -69.67 144.17 52.95 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 66.13 27.78 10.37 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 125.857 1.663 . . . . 0.0 111.516 -171.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p -144.86 146.15 31.93 Favored 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -173.68 -169.31 0.49 Allowed 'General case' 0 N--CA 1.43 -1.473 1 N-CA-C 97.571 -4.974 . . . . 0.0 97.571 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.6 pp -132.05 138.22 31.9 Favored Pre-proline 0 N--CA 1.43 -1.464 1 N-CA-C 96.456 -5.387 . . . . 0.0 96.456 155.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -59.93 167.25 21.51 Favored 'Cis proline' 0 C--N 1.324 -0.735 0 CA-C-N 122.734 2.012 . . . . 0.0 111.841 -23.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.7 tp -165.39 172.25 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 1 N-CA-C 94.711 -6.033 . . . . 0.0 94.711 178.252 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 78.2 mt -69.16 -34.25 74.69 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 119.315 0.962 . . . . 0.0 111.702 -165.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -144.22 140.01 29.03 Favored 'General case' 0 N--CA 1.43 -1.437 1 N-CA-C 97.182 -5.118 . . . . 0.0 97.182 165.255 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -103.43 154.62 19.23 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 -176.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.68 -170.11 42.87 Favored Glycine 0 N--CA 1.423 -2.203 1 N-CA-C 97.415 -6.274 . . . . 0.0 97.415 -175.15 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 21.9 tp -95.51 172.63 7.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 103.63 -2.73 . . . . 0.0 103.63 176.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m -84.49 149.52 25.88 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -142.79 172.13 13.11 Favored 'General case' 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 89.6 mt -145.43 163.2 35.38 Favored 'General case' 0 N--CA 1.421 -1.903 1 N-CA-C 94.567 -6.086 . . . . 0.0 94.567 168.051 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.873 0 O-C-N 124.13 0.894 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 . . . . . 0 N--CA 1.498 1.957 0 N-CA-C 102.32 -3.215 . . . . 0.0 102.32 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 75.72 -67.58 0.23 Allowed 'General case' 0 C--N 1.359 0.98 0 C-N-CA 125.57 1.548 . . . . 0.0 107.388 -164.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p -112.38 168.96 9.22 Favored 'General case' 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 172.126 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp -76.78 139.8 40.51 Favored 'General case' 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 71.05 24.11 4.02 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 126.64 1.976 . . . . 0.0 111.072 -173.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p -150.74 171.33 17.35 Favored 'General case' 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.9 p -167.9 179.42 4.71 Favored 'General case' 0 N--CA 1.416 -2.147 1 N-CA-C 96.502 -5.37 . . . . 0.0 96.502 175.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.96 138.92 27.21 Favored Pre-proline 0 N--CA 1.425 -1.715 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 156.821 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -62.85 163.67 47.18 Favored 'Cis proline' 0 N--CA 1.453 -0.894 0 CA-C-N 122.969 2.096 . . . . 0.0 111.048 -19.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -162.13 159.37 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.736 1 N-CA-C 95.098 -5.89 . . . . 0.0 95.098 168.549 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.7 mp -76.47 -32.99 58.71 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 123.654 0.781 . . . . 0.0 110.934 -161.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -123.17 131.33 53.64 Favored 'General case' 0 CA--C 1.485 -1.55 1 N-CA-C 97.329 -5.063 . . . . 0.0 97.329 169.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -132.14 169.67 16.07 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 -170.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.71 -171.63 44.58 Favored Glycine 0 N--CA 1.424 -2.124 1 N-CA-C 97.107 -6.397 . . . . 0.0 97.107 -178.126 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 70.5 mt -84.12 177.72 8.12 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 172.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m -89.92 147.29 23.81 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 165.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 -153.3 -171.76 4.02 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -133.61 161.49 34.49 Favored 'General case' 0 N--CA 1.426 -1.667 1 N-CA-C 94.426 -6.139 . . . . 0.0 94.426 162.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.964 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 . . . . . 0 N--CA 1.496 1.825 1 N-CA-C 98.29 -4.708 . . . . 0.0 98.29 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -93.38 -153.42 0.36 Allowed 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 101.365 -3.569 . . . . 0.0 101.365 147.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p -104.27 -172.5 2.12 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -76.34 138.09 40.25 Favored 'General case' 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 72.43 14.88 5.26 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 127.537 2.335 . . . . 0.0 111.492 -173.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.09 -90.91 0.45 Allowed 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -170.56 -176.02 2.01 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 100.638 -3.838 . . . . 0.0 100.638 -166.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -133.43 155.9 80.25 Favored Pre-proline 0 N--CA 1.426 -1.674 1 N-CA-C 94.935 -5.95 . . . . 0.0 94.935 170.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -62.68 166.76 36.13 Favored 'Cis proline' 0 CA--C 1.499 -1.232 0 CA-C-N 124.466 2.631 . . . . 0.0 112.718 -5.082 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 34.7 pt -89.83 172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.486 0 O-C-N 125.015 1.447 . . . . 0.0 107.89 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 94.2 mt 111.78 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.49 -1.335 0 C-N-CA 130.509 3.523 . . . . 0.0 104.335 174.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.1 mmtm -122.07 131.57 54.05 Favored 'General case' 0 CA--C 1.482 -1.657 1 N-CA-C 96.72 -5.289 . . . . 0.0 96.72 172.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -174.73 -60.61 0.01 OUTLIER 'General case' 0 CA--C 1.486 -1.498 1 N-CA-C 98.701 -4.555 . . . . 0.0 98.701 -171.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.54 143.03 27.66 Favored Glycine 0 N--CA 1.434 -1.444 0 N-CA-C 103.643 -3.783 . . . . 0.0 103.643 159.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -104.24 95.74 6.16 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.787 -3.042 . . . . 0.0 102.787 178.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m -90.29 154.37 19.76 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -140.38 163.5 32.62 Favored 'General case' 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -149.32 163.21 38.34 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.679 -6.045 . . . . 0.0 94.679 175.533 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.511 1.132 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 100.91 -3.737 . . . . 0.0 100.91 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -125.78 -76.55 0.58 Allowed 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 100.775 -3.787 . . . . 0.0 100.775 175.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p -124.45 174.4 7.8 Favored 'General case' 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 158.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -72.07 141.37 49.24 Favored 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 63.63 28.54 15.1 Favored 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 125.933 1.693 . . . . 0.0 112.996 -171.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p -123.01 166.88 14.37 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.2 p -150.6 158.73 44.49 Favored 'General case' 0 N--CA 1.425 -1.705 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 -164.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.9 mt -144.39 159.93 50.15 Favored Pre-proline 0 N--CA 1.431 -1.415 1 N-CA-C 96.263 -5.458 . . . . 0.0 96.263 178.65 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -64.77 160.66 69.56 Favored 'Cis proline' 0 CA--C 1.503 -1.064 0 CA-C-N 125.368 2.953 . . . . 0.0 110.983 -1.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 36.0 pt -88.19 137.52 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -175.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.4 mt -117.26 -68.15 0.94 Allowed 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 102.012 -3.329 . . . . 0.0 102.012 157.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -143.38 86.4 1.89 Allowed 'General case' 0 CA--C 1.487 -1.444 1 N-CA-C 99.025 -4.435 . . . . 0.0 99.025 167.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 10.1 p-10 178.95 -172.43 0.15 Allowed 'General case' 0 N--CA 1.43 -1.432 1 N-CA-C 97.402 -5.036 . . . . 0.0 97.402 -174.53 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.49 -62.95 4.52 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 108.13 -1.988 . . . . 0.0 108.13 -168.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 44.2 mt -69.2 117.66 11.12 Favored 'General case' 0 N--CA 1.434 -1.246 0 C-N-CA 126.303 1.841 . . . . 0.0 110.053 -171.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m -90.86 153.98 19.82 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 175.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -133.07 165.81 23.87 Favored 'General case' 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.7 mt -153.45 170.69 20.11 Favored 'General case' 0 N--CA 1.422 -1.86 1 N-CA-C 95.001 -5.925 . . . . 0.0 95.001 170.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.966 0 O-C-N 124.053 0.846 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 . . . . . 0 N--CA 1.498 1.972 0 N-CA-C 102.317 -3.216 . . . . 0.0 102.317 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -162.55 -179.13 6.69 Favored 'General case' 0 N--CA 1.426 -1.657 1 N-CA-C 98.475 -4.639 . . . . 0.0 98.475 176.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p 175.26 -175.01 0.09 Allowed 'General case' 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 -169.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -69.23 137.92 53.56 Favored 'General case' 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 60.75 30.75 19.9 Favored 'General case' 0 N--CA 1.44 -0.938 0 C-N-CA 127.2 2.2 . . . . 0.0 111.94 -169.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -124.74 9.82 8.31 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -19.98 60.15 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.786 1.635 . . . . 0.0 109.698 -179.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.2 mt -137.61 150.02 66.85 Favored Pre-proline 0 N--CA 1.419 -1.988 1 N-CA-C 95.4 -5.778 . . . . 0.0 95.4 167.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -64.8 150.55 74.48 Favored 'Cis proline' 0 CA--C 1.504 -1.006 0 CA-C-N 125.066 2.845 . . . . 0.0 109.736 -10.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.9 pt -134.3 137.25 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 1 N-CA-C 98.018 -4.808 . . . . 0.0 98.018 171.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 21.1 mt -171.41 -64.4 0.02 OUTLIER 'General case' 0 CA--C 1.488 -1.411 1 N-CA-C 97.783 -4.895 . . . . 0.0 97.783 -173.376 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.46 -101.32 0.43 Allowed 'General case' 0 N--CA 1.426 -1.649 1 N-CA-C 93.225 -6.583 . . . . 0.0 93.225 160.719 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -157.46 171.1 20.98 Favored 'General case' 0 CA--C 1.494 -1.204 1 N-CA-C 99.377 -4.305 . . . . 0.0 99.377 166.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -110.94 142.92 17.0 Favored Glycine 0 C--N 1.356 1.684 0 N-CA-C 104.054 -3.619 . . . . 0.0 104.054 173.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.6 mt -93.46 141.49 28.39 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-O 122.561 1.172 . . . . 0.0 111.425 -161.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m -90.34 152.28 21.09 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 126.084 1.754 . . . . 0.0 106.451 179.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -147.26 156.36 42.87 Favored 'General case' 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -154.99 161.29 41.42 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 94.8 -6.0 . . . . 0.0 94.8 172.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.945 0 O-C-N 124.164 0.915 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 . . . . . 0 N--CA 1.494 1.775 0 N-CA-C 105.631 -1.988 . . . . 0.0 105.631 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -166.55 -165.26 0.73 Allowed 'General case' 0 N--CA 1.434 -1.259 1 N-CA-C 96.613 -5.328 . . . . 0.0 96.613 -166.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.6 173.68 11.61 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 175.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.47 144.51 30.39 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 54.0 33.51 17.66 Favored 'General case' 0 CA--C 1.5 -0.966 0 C-N-CA 127.417 2.287 . . . . 0.0 112.346 -169.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p -147.4 170.59 17.04 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -179.26 178.47 0.7 Allowed 'General case' 0 N--CA 1.425 -1.715 1 N-CA-C 94.851 -5.981 . . . . 0.0 94.851 176.843 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.5 mt -149.74 166.42 15.27 Favored Pre-proline 0 CA--C 1.492 -1.273 1 N-CA-C 98.804 -4.517 . . . . 0.0 98.804 -171.725 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -71.24 -52.82 0.16 OUTLIER 'Cis proline' 0 CA--C 1.497 -1.365 0 CA-C-N 122.396 1.891 . . . . 0.0 109.851 -10.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.266 54.7 mt 80.63 -91.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 C-N-CA 127.979 2.512 . . . . 0.0 105.732 -175.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -144.65 175.03 10.46 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 96.142 -5.503 . . . . 0.0 96.142 175.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -78.1 74.83 4.64 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 119.061 0.846 . . . . 0.0 111.019 -170.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 74.1 m-80 -77.41 -87.61 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.212 0 C-N-CA 125.934 1.693 . . . . 0.0 106.708 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.47 -163.05 35.72 Favored Glycine 0 N--CA 1.42 -2.429 1 N-CA-C 98.414 -5.874 . . . . 0.0 98.414 174.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.4 mt -91.57 -155.15 0.39 Allowed 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m -89.83 153.33 20.74 Favored 'General case' 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 177.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.404 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.404 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -154.99 173.02 17.14 Favored 'General case' 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 84.3 mt -141.09 146.6 37.32 Favored 'General case' 0 N--CA 1.421 -1.893 1 N-CA-C 93.189 -6.596 . . . . 0.0 93.189 169.479 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.846 0 O-C-N 124.322 1.013 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 . . . . . 0 N--CA 1.448 -0.537 0 CA-C-O 121.223 0.535 . . . . 0.0 112.162 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m . . . . . 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm . . . . . 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 . . . . . 0 CA--C 1.502 -0.866 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p . . . . . 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 . . . . . 0 CA--C 1.5 -0.978 0 CA-C-O 120.777 0.323 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p . . . . . 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m . . . . . 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p . . . . . 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt . . . . . 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 . . . . . 0 CA--C 1.5 -0.952 0 CA-C-O 121.075 0.464 . . . . 0.0 111.633 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m . . . . . 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 . . . . . 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm . . . . . 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.442 -0.83 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m . . . . . 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 29' ' ' CYS . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 . . . . . 0 CA--C 1.505 -0.762 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p . . . . . 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m . . . . . 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt . . . . . 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 . . . . . 0 CA--C 1.505 -0.768 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 . . . . . 0 CA--C 1.505 -0.759 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm . . . . . 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m . . . . . 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.465 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.465 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 . . . . . 0 N--CA 1.442 -0.835 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 9' ' ' PHE . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm . . . . . 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 CA--C 1.502 -0.869 0 CA-C-O 120.513 0.197 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m . . . . . 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 . . . . . 0 CA--C 1.501 -0.924 0 CA-C-O 121.118 0.485 . . . . 0.0 111.516 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m . . . . . 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 . . . . . 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp . . . . . 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 . . . . . 0 N--CA 1.443 -0.797 0 CA-C-O 120.682 0.277 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p . . . . . 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 . . . . . 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p . . . . . 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm . . . . . 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 CA--C 1.503 -0.834 0 CA-C-O 120.764 0.316 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m . . . . . 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm . . . . . 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m . . . . . 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp . . . . . 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 . . . . . 0 N--CA 1.44 -0.938 0 CA-C-O 121.131 0.491 . . . . 0.0 111.94 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m . . . . . 0 N--CA 1.432 -1.37 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p . . . . . 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 . . . . . 0 CA--C 1.5 -0.966 0 CA-C-O 121.667 0.746 . . . . 0.0 112.346 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p . . . . . 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m . . . . . 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.497 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.497 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 38.8 t70 . . . . . 0 N--CA 1.494 1.748 0 N-CA-C 102.974 -2.973 . . . . 0.0 102.974 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -172.67 -170.68 0.71 Allowed 'General case' 0 N--CA 1.43 -1.442 1 N-CA-C 97.104 -5.147 . . . . 0.0 97.104 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p -105.74 172.38 6.83 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 172.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -82.71 141.62 32.28 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 66.5 23.22 10.51 Favored 'General case' 0 C--N 1.357 0.933 0 C-N-CA 125.898 1.679 . . . . 0.0 112.162 -172.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -111.21 -123.31 0.27 Allowed 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.6 p -153.96 -160.2 1.07 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 102.754 -3.054 . . . . 0.0 102.754 173.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.7 mt -148.99 165.05 18.68 Favored Pre-proline 0 N--CA 1.43 -1.469 1 N-CA-C 97.491 -5.003 . . . . 0.0 97.491 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -64.01 144.5 55.77 Favored 'Cis proline' 0 CA--C 1.504 -0.986 0 CA-C-N 124.088 2.496 . . . . 0.0 109.74 -6.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -107.45 108.61 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.304 0 N-CA-C 105.372 -2.084 . . . . 0.0 105.372 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.2 mp -137.45 -63.13 0.6 Allowed 'General case' 0 CA--C 1.487 -1.448 1 N-CA-C 99.447 -4.279 . . . . 0.0 99.447 162.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.2 tmtm? -112.41 148.0 35.25 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 95.579 -5.711 . . . . 0.0 95.579 161.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -162.05 -166.66 1.47 Allowed 'General case' 0 N--CA 1.431 -1.408 1 N-CA-C 97.758 -4.904 . . . . 0.0 97.758 177.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -74.46 131.47 13.24 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 105.849 -2.9 . . . . 0.0 105.849 173.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -88.33 133.45 34.07 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -159.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m -90.36 150.88 21.7 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -138.09 161.76 35.94 Favored 'General case' 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 62.3 mt -153.59 167.59 29.03 Favored 'General case' 0 N--CA 1.424 -1.754 1 N-CA-C 94.934 -5.95 . . . . 0.0 94.934 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.955 0 O-C-N 124.225 0.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.495 1.796 0 N-CA-C 102.041 -3.318 . . . . 0.0 102.041 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -143.61 159.09 43.08 Favored 'General case' 0 N--CA 1.427 -1.601 1 N-CA-C 95.389 -5.782 . . . . 0.0 95.389 175.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p -176.46 -177.88 0.88 Allowed 'General case' 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 -178.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -75.29 140.35 43.08 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 64.39 30.19 13.26 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 127.933 2.493 . . . . 0.0 112.675 -171.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p -120.46 -18.02 7.98 Favored 'General case' 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -74.09 -69.8 0.42 Allowed 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -160.14 164.39 19.95 Favored Pre-proline 0 N--CA 1.421 -1.898 1 N-CA-C 97.704 -4.925 . . . . 0.0 97.704 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -68.09 167.06 65.46 Favored 'Cis proline' 0 CA--C 1.5 -1.184 0 CA-C-N 124.683 2.708 . . . . 0.0 110.459 -1.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.408 HG22 ' H ' ' A' ' 14' ' ' ILE . 3.3 tp -75.44 97.18 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.184 0 CA-C-O 122.371 1.082 . . . . 0.0 108.09 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -109.56 -53.68 2.63 Favored 'General case' 0 CA--C 1.483 -1.634 0 N-CA-C 102.527 -3.138 . . . . 0.0 102.527 163.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -138.63 160.9 38.48 Favored 'General case' 0 N--CA 1.418 -2.074 1 N-CA-C 94.906 -5.961 . . . . 0.0 94.906 153.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -123.19 145.49 48.59 Favored 'General case' 0 CA--C 1.492 -1.275 1 N-CA-C 97.966 -4.827 . . . . 0.0 97.966 168.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.15 -134.75 9.95 Favored Glycine 0 C--N 1.35 1.352 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 169.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 45.3 tp -73.57 127.88 33.95 Favored 'General case' 0 C--N 1.36 1.056 0 C-N-CA 125.815 1.646 . . . . 0.0 113.036 -159.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m -90.26 148.01 23.17 Favored 'General case' 0 CA--C 1.493 -1.24 0 C-N-CA 124.738 1.215 . . . . 0.0 108.407 174.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -139.72 171.01 14.85 Favored 'General case' 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.8 mt -147.71 156.24 42.55 Favored 'General case' 0 N--CA 1.422 -1.833 1 N-CA-C 93.89 -6.337 . . . . 0.0 93.89 173.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.838 0 O-C-N 124.507 1.129 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 N--CA 1.487 1.386 0 N-CA-C 102.585 -3.117 . . . . 0.0 102.585 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 61.9 t0 -97.29 -71.99 0.66 Allowed 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 104.816 -2.29 . . . . 0.0 104.816 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p -146.73 172.43 13.64 Favored 'General case' 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 173.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -86.39 135.88 33.34 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 79.69 1.78 2.17 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 127.119 2.168 . . . . 0.0 110.463 -176.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p -99.51 91.67 5.02 Favored 'General case' 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.02 162.08 25.06 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 175.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 96.4 mt -137.46 159.99 67.16 Favored Pre-proline 0 N--CA 1.435 -1.179 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 170.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -64.65 148.66 71.43 Favored 'Cis proline' 0 CA--C 1.506 -0.913 0 CA-C-N 126.78 3.457 . . . . 0.0 114.224 14.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.9 tt -72.1 -24.45 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 C-N-CA 125.553 1.541 . . . . 0.0 110.863 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 70.4 mt -75.03 -32.5 61.6 Favored 'General case' 0 CA--C 1.5 -0.953 0 O-C-N 121.38 -0.825 . . . . 0.0 109.979 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmtp -82.9 -53.0 6.19 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.4 m-80 -89.57 -109.63 0.08 Allowed 'General case' 0 N--CA 1.442 -0.826 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 -170.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 166.16 -151.89 20.62 Favored Glycine 0 CA--C 1.474 -2.502 1 N-CA-C 99.303 -5.519 . . . . 0.0 99.303 175.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 82.2 mt -113.76 177.45 4.63 Favored 'General case' 0 N--CA 1.432 -1.341 0 N-CA-C 102.182 -3.266 . . . . 0.0 102.182 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m -89.06 141.61 28.35 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 -176.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -142.54 170.25 16.05 Favored 'General case' 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.9 mt -147.77 167.82 23.72 Favored 'General case' 0 N--CA 1.423 -1.808 1 N-CA-C 94.345 -6.169 . . . . 0.0 94.345 174.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.869 0 O-C-N 124.351 1.032 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 . . . . . 0 N--CA 1.505 2.296 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -82.89 -170.15 2.86 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 151.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.39 -169.26 3.31 Favored 'General case' 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 178.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.436 HD11 HD22 ' A' ' 17' ' ' ASN . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -81.66 140.98 34.05 Favored 'General case' 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 64.12 28.1 14.13 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 126.184 1.794 . . . . 0.0 111.633 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -119.95 123.43 43.51 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -133.58 159.19 41.19 Favored 'General case' 0 N--CA 1.431 -1.398 1 N-CA-C 94.649 -6.056 . . . . 0.0 94.649 161.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 pp -155.42 160.76 30.6 Favored Pre-proline 0 N--CA 1.425 -1.677 0 N-CA-C 101.124 -3.658 . . . . 0.0 101.124 178.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.66 167.87 72.39 Favored 'Cis proline' 0 N--CA 1.453 -0.887 0 N-CA-C 108.92 -1.223 . . . . 0.0 108.92 -23.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tt -150.03 -46.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 N-CA-C 102.502 -3.147 . . . . 0.0 102.502 178.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 86.7 mt -117.33 -151.73 0.49 Allowed 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 101.726 -3.435 . . . . 0.0 101.726 167.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.4 mptp? -91.81 59.96 3.8 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 170.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 4' ' ' ILE . 6.0 p-10 -83.84 -122.71 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 124.921 1.288 . . . . 0.0 108.579 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 150.67 -144.15 11.48 Favored Glycine 0 CA--C 1.475 -2.439 1 N-CA-C 98.677 -5.769 . . . . 0.0 98.677 -174.117 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.7 mt -84.64 -167.09 1.66 Allowed 'General case' 0 N--CA 1.438 -1.061 0 O-C-N 125.116 1.127 . . . . 0.0 108.435 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m -90.39 150.29 21.92 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -173.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -109.98 -179.61 3.84 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 tp -162.1 164.34 28.1 Favored 'General case' 0 N--CA 1.421 -1.894 1 N-CA-C 96.111 -5.515 . . . . 0.0 96.111 -177.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.027 0 O-C-N 124.226 0.954 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 101.881 -3.377 . . . . 0.0 101.881 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.96 -24.77 59.68 Favored 'General case' 0 C--N 1.352 0.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.26 176.212 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -138.81 -167.86 2.29 Favored 'General case' 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 173.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -73.69 143.2 46.3 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 65.67 27.98 11.23 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.69 1.996 . . . . 0.0 112.153 -173.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p -113.83 151.93 31.4 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.91 159.68 21.26 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 165.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 16.0 mt -156.67 165.15 19.36 Favored Pre-proline 0 N--CA 1.434 -1.25 1 N-CA-C 97.668 -4.938 . . . . 0.0 97.668 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -69.72 -77.24 0.0 OUTLIER 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 125.13 2.868 . . . . 0.0 110.988 -2.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tp -129.0 121.33 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.741 1 N-CA-C 97.583 -4.969 . . . . 0.0 97.583 167.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.6 mt -140.44 -98.19 0.15 Allowed 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -129.23 130.38 46.19 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 96.512 -5.366 . . . . 0.0 96.512 157.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 177.19 -173.35 0.11 Allowed 'General case' 0 N--CA 1.426 -1.671 1 N-CA-C 97.209 -5.108 . . . . 0.0 97.209 -168.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.69 -170.53 42.94 Favored Glycine 0 N--CA 1.424 -2.166 1 N-CA-C 97.314 -6.314 . . . . 0.0 97.314 -177.349 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.13 172.13 12.99 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 177.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m -90.29 163.4 14.77 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 175.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 29' ' ' CYS . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -141.4 174.53 10.46 Favored 'General case' 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -83.59 71.93 10.33 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.167 0 CA-C-N 116.383 -0.371 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -89.8 -165.35 1.33 Allowed 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 103.822 -2.658 . . . . 0.0 103.822 157.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -151.91 -176.07 5.49 Favored 'General case' 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -78.76 144.45 35.18 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 70.82 18.58 6.12 Favored 'General case' 0 C--N 1.356 0.865 0 C-N-CA 126.572 1.949 . . . . 0.0 112.397 -175.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p -106.14 164.69 11.79 Favored 'General case' 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.8 p -164.09 -125.24 0.02 OUTLIER 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 -166.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 95.7 mt -155.58 171.1 7.7 Favored Pre-proline 0 N--CA 1.425 -1.687 1 N-CA-C 98.593 -4.595 . . . . 0.0 98.593 -161.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -64.56 135.27 21.38 Favored 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 123.093 2.14 . . . . 0.0 109.922 -16.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.8 pt -73.04 155.73 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.068 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 53.4 mt 79.08 -35.47 0.16 Allowed 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 126.187 1.795 . . . . 0.0 110.717 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -76.39 -62.43 1.62 Allowed 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -133.85 -129.63 0.17 Allowed 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 100.631 -3.84 . . . . 0.0 100.631 173.369 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 84.52 -58.59 4.98 Favored Glycine 0 CA--C 1.487 -1.676 0 N-CA-C 110.326 -1.11 . . . . 0.0 110.326 168.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 83.2 mt -81.98 149.31 28.22 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m -90.54 151.89 21.15 Favored 'General case' 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.42 173.65 7.02 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.2 mp -84.43 68.2 10.17 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.174 0 CA-C-N 116.499 -0.319 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.497 1.906 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -158.42 179.52 9.06 Favored 'General case' 0 N--CA 1.43 -1.451 1 N-CA-C 96.778 -5.267 . . . . 0.0 96.778 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.34 160.59 34.56 Favored 'General case' 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 168.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -65.87 138.92 58.2 Favored 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 68.12 20.76 8.88 Favored 'General case' 0 C--N 1.355 0.824 0 C-N-CA 125.531 1.532 . . . . 0.0 112.175 -175.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.6 -115.0 0.3 Allowed 'General case' 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.4 p -167.15 -163.3 0.52 Allowed 'General case' 0 N--CA 1.427 -1.599 1 N-CA-C 98.046 -4.798 . . . . 0.0 98.046 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 19.0 mt -150.42 167.76 12.35 Favored Pre-proline 0 N--CA 1.429 -1.496 1 N-CA-C 97.512 -4.996 . . . . 0.0 97.512 176.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -66.99 151.96 83.43 Favored 'Cis proline' 0 CA--C 1.504 -1.004 0 CA-C-N 122.988 2.103 . . . . 0.0 109.992 -9.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.2 tp -99.9 102.05 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 99.4 mt -124.72 -79.08 0.61 Allowed 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 100.659 -3.83 . . . . 0.0 100.659 165.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.7 mttp -132.03 145.33 51.37 Favored 'General case' 0 N--CA 1.424 -1.747 1 N-CA-C 95.213 -5.847 . . . . 0.0 95.213 154.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -160.36 -50.06 0.05 OUTLIER 'General case' 0 CA--C 1.487 -1.467 0 N-CA-C 100.855 -3.757 . . . . 0.0 100.855 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.5 -172.42 13.27 Favored Glycine 0 N--CA 1.427 -1.926 1 N-CA-C 98.6 -5.8 . . . . 0.0 98.6 162.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.4 tp -137.33 131.95 32.91 Favored 'General case' 0 CA--C 1.483 -1.63 1 N-CA-C 99.285 -4.339 . . . . 0.0 99.285 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m -90.71 150.11 21.77 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.199 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.13 164.5 30.5 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -85.87 66.91 9.84 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 -173.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.128 0 CA-C-N 116.587 -0.279 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 100.917 -3.734 . . . . 0.0 100.917 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.79 -77.75 0.36 Allowed 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.793 -1.929 . . . . 0.0 105.793 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -140.17 170.76 15.23 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 176.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp -79.5 137.57 37.25 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 70.22 19.88 6.45 Favored 'General case' 0 C--N 1.355 0.837 0 C-N-CA 127.345 2.258 . . . . 0.0 112.585 -174.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p -137.15 170.27 16.38 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -169.21 174.64 6.05 Favored 'General case' 0 N--CA 1.424 -1.751 1 N-CA-C 98.008 -4.812 . . . . 0.0 98.008 -163.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -143.81 162.04 43.13 Favored Pre-proline 0 N--CA 1.433 -1.318 1 N-CA-C 97.841 -4.874 . . . . 0.0 97.841 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -63.07 145.28 53.31 Favored 'Cis proline' 0 CA--C 1.503 -1.049 0 CA-C-N 126.154 3.233 . . . . 0.0 115.328 17.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.3 tt -69.83 149.18 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.941 0 C-N-CA 125.404 1.481 . . . . 0.0 108.195 -174.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 67.5 mt 75.19 -48.58 0.63 Allowed 'General case' 0 C--N 1.356 0.885 0 C-N-CA 127.607 2.363 . . . . 0.0 111.172 178.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -64.69 -44.79 89.16 Favored 'General case' 0 CA--C 1.504 -0.824 0 C-N-CA 125.429 1.491 . . . . 0.0 107.743 177.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -80.5 -70.07 0.55 Allowed 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 166.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.26 -143.49 8.6 Favored Glycine 0 N--CA 1.422 -2.264 1 N-CA-C 98.706 -5.758 . . . . 0.0 98.706 172.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -152.46 -179.63 7.74 Favored 'General case' 0 N--CA 1.426 -1.661 1 N-CA-C 95.255 -5.831 . . . . 0.0 95.255 161.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m -89.47 143.88 26.47 Favored 'General case' 0 CA--C 1.489 -1.372 0 CA-C-N 120.439 1.472 . . . . 0.0 107.388 -173.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -124.88 -163.59 1.2 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.6 tp -135.02 143.16 46.62 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 94.357 -6.164 . . . . 0.0 94.357 172.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.271 0.982 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.1 m-20 . . . . . 0 N--CA 1.498 1.968 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -148.38 161.76 40.94 Favored 'General case' 0 N--CA 1.431 -1.404 1 N-CA-C 94.961 -5.94 . . . . 0.0 94.961 171.588 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p -153.51 163.75 39.41 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 -178.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -74.89 143.97 43.56 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 70.3 22.55 5.37 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 126.487 1.915 . . . . 0.0 113.003 -176.096 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p -107.03 176.59 5.12 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.7 p -151.04 168.21 25.31 Favored 'General case' 0 N--CA 1.419 -1.983 1 N-CA-C 98.765 -4.532 . . . . 0.0 98.765 -173.386 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 92.3 mt -144.12 157.16 57.62 Favored Pre-proline 0 N--CA 1.425 -1.722 1 N-CA-C 95.497 -5.742 . . . . 0.0 95.497 175.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.13 164.22 74.68 Favored 'Cis proline' 0 CA--C 1.503 -1.05 0 CA-C-N 124.764 2.737 . . . . 0.0 110.582 5.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -85.36 119.48 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.3 mt -137.0 -77.09 0.41 Allowed 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 103.902 -2.629 . . . . 0.0 103.902 174.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 mtpt -134.12 47.5 2.41 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 -178.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 176.91 175.41 0.37 Allowed 'General case' 0 N--CA 1.427 -1.615 1 N-CA-C 96.465 -5.383 . . . . 0.0 96.465 -164.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.04 -51.53 0.69 Allowed Glycine 0 CA--C 1.484 -1.89 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 173.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.0 mt -80.63 130.95 35.41 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m -90.7 147.15 23.45 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 167.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -143.85 156.35 44.43 Favored 'General case' 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.8 mt -155.63 163.89 39.33 Favored 'General case' 0 N--CA 1.423 -1.777 1 N-CA-C 94.554 -6.091 . . . . 0.0 94.554 176.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.234 0.959 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.6 t70 69.66 -103.69 0.05 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 125.557 1.543 . . . . 0.0 108.402 -175.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p -134.4 168.43 18.93 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 174.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm -89.78 141.38 28.68 Favored 'General case' 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 65.32 25.98 12.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 C-N-CA 127.431 2.292 . . . . 0.0 112.891 -174.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -146.61 -177.65 5.75 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 p -167.44 176.91 6.29 Favored 'General case' 0 N--CA 1.417 -2.096 1 N-CA-C 99.874 -4.121 . . . . 0.0 99.874 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -139.89 157.72 69.0 Favored Pre-proline 0 N--CA 1.424 -1.733 1 N-CA-C 94.366 -6.161 . . . . 0.0 94.366 160.503 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -68.31 172.54 42.61 Favored 'Cis proline' 0 C--N 1.319 -1.023 0 CA-C-N 124.461 2.629 . . . . 0.0 110.941 -8.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.487 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.0 OUTLIER -77.84 121.59 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 C-N-CA 125.388 1.475 . . . . 0.0 109.626 -170.731 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.92 -64.0 1.29 Allowed 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 103.694 -2.706 . . . . 0.0 103.694 172.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -152.24 42.01 0.65 Allowed 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 103.167 -2.901 . . . . 0.0 103.167 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -90.49 -144.37 0.17 Allowed 'General case' 0 CA--C 1.5 -0.972 0 C-N-CA 125.229 1.412 . . . . 0.0 107.349 -164.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.19 -165.61 38.7 Favored Glycine 0 N--CA 1.421 -2.312 1 N-CA-C 97.218 -6.353 . . . . 0.0 97.218 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -86.45 174.31 9.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 170.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m -90.31 140.3 29.83 Favored 'General case' 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 166.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.465 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.63 171.84 11.29 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 23.0 mt -155.08 167.73 29.38 Favored 'General case' 0 N--CA 1.424 -1.737 1 N-CA-C 95.285 -5.82 . . . . 0.0 95.285 -176.103 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.359 0.994 0 O-C-N 123.894 0.746 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.498 1.945 0 N-CA-C 104.882 -2.266 . . . . 0.0 104.882 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.2 m-20 -154.47 -177.44 6.47 Favored 'General case' 0 N--CA 1.431 -1.383 1 N-CA-C 96.183 -5.488 . . . . 0.0 96.183 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p -161.91 -175.94 4.94 Favored 'General case' 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -76.16 144.06 40.77 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 70.58 20.55 5.77 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 127.753 2.421 . . . . 0.0 111.851 -173.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -137.77 -174.44 3.78 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.95 165.56 33.82 Favored 'General case' 0 N--CA 1.425 -1.679 1 N-CA-C 97.502 -4.999 . . . . 0.0 97.502 179.021 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -168.51 173.57 2.54 Favored Pre-proline 0 N--CA 1.431 -1.398 1 N-CA-C 98.831 -4.507 . . . . 0.0 98.831 -170.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -64.6 -62.25 0.03 OUTLIER 'Cis proline' 0 CA--C 1.498 -1.296 0 CA-C-N 125.753 3.09 . . . . 0.0 108.64 -1.536 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.346 2.8 mt 42.08 -112.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 C-N-CA 128.694 2.798 . . . . 0.0 112.83 177.603 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 60.7 mt -134.66 -146.71 0.26 Allowed 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -74.27 10.17 1.37 Allowed 'General case' 0 C--N 1.358 0.937 0 C-N-CA 124.538 1.135 . . . . 0.0 112.989 -173.383 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -70.84 -26.04 63.1 Favored 'General case' 0 C--N 1.35 0.625 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 163.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.99 29.59 7.91 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 176.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -117.15 104.38 11.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 176.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m -90.81 149.62 21.9 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 172.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 9' ' ' PHE . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.48 155.83 40.27 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -169.62 173.08 6.53 Favored 'General case' 0 N--CA 1.423 -1.819 1 N-CA-C 95.693 -5.669 . . . . 0.0 95.693 173.804 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.89 0 O-C-N 124.203 0.94 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 . . . . . 0 N--CA 1.498 1.974 0 N-CA-C 102.552 -3.129 . . . . 0.0 102.552 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -156.47 166.31 33.79 Favored 'General case' 0 N--CA 1.428 -1.567 1 N-CA-C 95.652 -5.684 . . . . 0.0 95.652 175.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p -168.25 177.87 5.23 Favored 'General case' 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 -177.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -86.96 143.66 27.27 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 76.18 11.89 2.84 Favored 'General case' 0 CA--C 1.502 -0.869 0 C-N-CA 127.015 2.126 . . . . 0.0 111.304 -178.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p -134.36 -157.81 0.83 Allowed 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 p -173.23 -177.13 1.47 Allowed 'General case' 0 N--CA 1.425 -1.703 1 N-CA-C 98.324 -4.695 . . . . 0.0 98.324 -179.028 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -160.14 165.75 17.13 Favored Pre-proline 0 N--CA 1.428 -1.558 1 N-CA-C 99.111 -4.403 . . . . 0.0 99.111 178.315 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -63.77 -65.42 0.03 OUTLIER 'Cis proline' 0 CA--C 1.503 -1.065 0 CA-C-N 125.702 3.072 . . . . 0.0 111.69 0.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -133.72 132.65 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.678 1 N-CA-C 97.024 -5.176 . . . . 0.0 97.024 167.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.4 mt -167.12 -96.8 0.01 OUTLIER 'General case' 0 N--CA 1.434 -1.264 1 N-CA-C 95.031 -5.914 . . . . 0.0 95.031 -179.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -106.47 97.51 7.3 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 102.994 -2.965 . . . . 0.0 102.994 162.479 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -155.65 178.39 10.3 Favored 'General case' 0 CA--C 1.491 -1.321 1 N-CA-C 97.131 -5.137 . . . . 0.0 97.131 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.84 -84.55 0.11 Allowed Glycine 0 CA--C 1.476 -2.382 1 N-CA-C 101.757 -4.537 . . . . 0.0 101.757 175.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 99.3 mt -139.29 146.06 39.9 Favored 'General case' 0 N--CA 1.419 -1.992 1 N-CA-C 96.677 -5.305 . . . . 0.0 96.677 167.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m -90.95 142.95 27.23 Favored 'General case' 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 151.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -145.57 155.02 42.79 Favored 'General case' 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -171.52 175.82 3.96 Favored 'General case' 0 N--CA 1.424 -1.735 1 N-CA-C 96.012 -5.551 . . . . 0.0 96.012 177.493 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.944 0 O-C-N 124.231 0.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 . . . . . 0 N--CA 1.49 1.553 1 N-CA-C 99.669 -4.197 . . . . 0.0 99.669 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -70.48 -47.76 59.03 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 163.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -96.44 169.97 9.55 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 173.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -69.67 144.17 52.95 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 66.13 27.78 10.37 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 125.857 1.663 . . . . 0.0 111.516 -171.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p -144.86 146.15 31.93 Favored 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -173.68 -169.31 0.49 Allowed 'General case' 0 N--CA 1.43 -1.473 1 N-CA-C 97.571 -4.974 . . . . 0.0 97.571 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.6 pp -132.05 138.22 31.9 Favored Pre-proline 0 N--CA 1.43 -1.464 1 N-CA-C 96.456 -5.387 . . . . 0.0 96.456 155.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -59.93 167.25 21.51 Favored 'Cis proline' 0 C--N 1.324 -0.735 0 CA-C-N 122.734 2.012 . . . . 0.0 111.841 -23.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.7 tp -165.39 172.25 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 1 N-CA-C 94.711 -6.033 . . . . 0.0 94.711 178.252 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 78.2 mt -69.16 -34.25 74.69 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 119.315 0.962 . . . . 0.0 111.702 -165.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -144.22 140.01 29.03 Favored 'General case' 0 N--CA 1.43 -1.437 1 N-CA-C 97.182 -5.118 . . . . 0.0 97.182 165.255 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -103.43 154.62 19.23 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 -176.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.68 -170.11 42.87 Favored Glycine 0 N--CA 1.423 -2.203 1 N-CA-C 97.415 -6.274 . . . . 0.0 97.415 -175.15 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 21.9 tp -95.51 172.63 7.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 103.63 -2.73 . . . . 0.0 103.63 176.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m -84.49 149.52 25.88 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -142.79 172.13 13.11 Favored 'General case' 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 89.6 mt -145.43 163.2 35.38 Favored 'General case' 0 N--CA 1.421 -1.903 1 N-CA-C 94.567 -6.086 . . . . 0.0 94.567 168.051 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.873 0 O-C-N 124.13 0.894 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 . . . . . 0 N--CA 1.498 1.957 0 N-CA-C 102.32 -3.215 . . . . 0.0 102.32 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 75.72 -67.58 0.23 Allowed 'General case' 0 C--N 1.359 0.98 0 C-N-CA 125.57 1.548 . . . . 0.0 107.388 -164.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p -112.38 168.96 9.22 Favored 'General case' 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 172.126 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp -76.78 139.8 40.51 Favored 'General case' 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 71.05 24.11 4.02 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 126.64 1.976 . . . . 0.0 111.072 -173.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p -150.74 171.33 17.35 Favored 'General case' 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.9 p -167.9 179.42 4.71 Favored 'General case' 0 N--CA 1.416 -2.147 1 N-CA-C 96.502 -5.37 . . . . 0.0 96.502 175.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.96 138.92 27.21 Favored Pre-proline 0 N--CA 1.425 -1.715 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 156.821 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -62.85 163.67 47.18 Favored 'Cis proline' 0 N--CA 1.453 -0.894 0 CA-C-N 122.969 2.096 . . . . 0.0 111.048 -19.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -162.13 159.37 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.736 1 N-CA-C 95.098 -5.89 . . . . 0.0 95.098 168.549 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.7 mp -76.47 -32.99 58.71 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 123.654 0.781 . . . . 0.0 110.934 -161.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -123.17 131.33 53.64 Favored 'General case' 0 CA--C 1.485 -1.55 1 N-CA-C 97.329 -5.063 . . . . 0.0 97.329 169.036 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 41.7 t30 -132.14 169.67 16.07 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 -170.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.71 -171.63 44.58 Favored Glycine 0 N--CA 1.424 -2.124 1 N-CA-C 97.107 -6.397 . . . . 0.0 97.107 -178.126 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 70.5 mt -84.12 177.72 8.12 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 172.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m -89.92 147.29 23.81 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 165.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 -153.3 -171.76 4.02 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -133.61 161.49 34.49 Favored 'General case' 0 N--CA 1.426 -1.667 1 N-CA-C 94.426 -6.139 . . . . 0.0 94.426 162.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.964 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 . . . . . 0 N--CA 1.496 1.825 1 N-CA-C 98.29 -4.708 . . . . 0.0 98.29 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -93.38 -153.42 0.36 Allowed 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 101.365 -3.569 . . . . 0.0 101.365 147.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p -104.27 -172.5 2.12 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -76.34 138.09 40.25 Favored 'General case' 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 72.43 14.88 5.26 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 127.537 2.335 . . . . 0.0 111.492 -173.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.09 -90.91 0.45 Allowed 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -170.56 -176.02 2.01 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 100.638 -3.838 . . . . 0.0 100.638 -166.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -133.43 155.9 80.25 Favored Pre-proline 0 N--CA 1.426 -1.674 1 N-CA-C 94.935 -5.95 . . . . 0.0 94.935 170.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -62.68 166.76 36.13 Favored 'Cis proline' 0 CA--C 1.499 -1.232 0 CA-C-N 124.466 2.631 . . . . 0.0 112.718 -5.082 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 34.7 pt -89.83 172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.486 0 O-C-N 125.015 1.447 . . . . 0.0 107.89 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 94.2 mt 111.78 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.49 -1.335 0 C-N-CA 130.509 3.523 . . . . 0.0 104.335 174.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.1 mmtm -122.07 131.57 54.05 Favored 'General case' 0 CA--C 1.482 -1.657 1 N-CA-C 96.72 -5.289 . . . . 0.0 96.72 172.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -174.73 -60.61 0.01 OUTLIER 'General case' 0 CA--C 1.486 -1.498 1 N-CA-C 98.701 -4.555 . . . . 0.0 98.701 -171.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.54 143.03 27.66 Favored Glycine 0 N--CA 1.434 -1.444 0 N-CA-C 103.643 -3.783 . . . . 0.0 103.643 159.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -104.24 95.74 6.16 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.787 -3.042 . . . . 0.0 102.787 178.301 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m -90.29 154.37 19.76 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -140.38 163.5 32.62 Favored 'General case' 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -149.32 163.21 38.34 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.679 -6.045 . . . . 0.0 94.679 175.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.511 1.132 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 100.91 -3.737 . . . . 0.0 100.91 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -125.78 -76.55 0.58 Allowed 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 100.775 -3.787 . . . . 0.0 100.775 175.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p -124.45 174.4 7.8 Favored 'General case' 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 158.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.441 HD11 ' HB2' ' A' ' 17' ' ' ASN . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -72.07 141.37 49.24 Favored 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 63.63 28.54 15.1 Favored 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 125.933 1.693 . . . . 0.0 112.996 -171.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p -123.01 166.88 14.37 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.2 p -150.6 158.73 44.49 Favored 'General case' 0 N--CA 1.425 -1.705 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 -164.127 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.9 mt -144.39 159.93 50.15 Favored Pre-proline 0 N--CA 1.431 -1.415 1 N-CA-C 96.263 -5.458 . . . . 0.0 96.263 178.65 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -64.77 160.66 69.56 Favored 'Cis proline' 0 CA--C 1.503 -1.064 0 CA-C-N 125.368 2.953 . . . . 0.0 110.983 -1.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 36.0 pt -88.19 137.52 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -175.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.4 mt -117.26 -68.15 0.94 Allowed 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 102.012 -3.329 . . . . 0.0 102.012 157.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -143.38 86.4 1.89 Allowed 'General case' 0 CA--C 1.487 -1.444 1 N-CA-C 99.025 -4.435 . . . . 0.0 99.025 167.636 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.441 ' HB2' HD11 ' A' ' 4' ' ' ILE . 10.1 p-10 178.95 -172.43 0.15 Allowed 'General case' 0 N--CA 1.43 -1.432 1 N-CA-C 97.402 -5.036 . . . . 0.0 97.402 -174.53 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.49 -62.95 4.52 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 108.13 -1.988 . . . . 0.0 108.13 -168.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 44.2 mt -69.2 117.66 11.12 Favored 'General case' 0 N--CA 1.434 -1.246 0 C-N-CA 126.303 1.841 . . . . 0.0 110.053 -171.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m -90.86 153.98 19.82 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 175.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -133.07 165.81 23.87 Favored 'General case' 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.7 mt -153.45 170.69 20.11 Favored 'General case' 0 N--CA 1.422 -1.86 1 N-CA-C 95.001 -5.925 . . . . 0.0 95.001 170.337 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.966 0 O-C-N 124.053 0.846 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 . . . . . 0 N--CA 1.498 1.972 0 N-CA-C 102.317 -3.216 . . . . 0.0 102.317 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -162.55 -179.13 6.69 Favored 'General case' 0 N--CA 1.426 -1.657 1 N-CA-C 98.475 -4.639 . . . . 0.0 98.475 176.046 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p 175.26 -175.01 0.09 Allowed 'General case' 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 -169.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -69.23 137.92 53.56 Favored 'General case' 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 60.75 30.75 19.9 Favored 'General case' 0 N--CA 1.44 -0.938 0 C-N-CA 127.2 2.2 . . . . 0.0 111.94 -169.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -124.74 9.82 8.31 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -19.98 60.15 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.786 1.635 . . . . 0.0 109.698 -179.346 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.2 mt -137.61 150.02 66.85 Favored Pre-proline 0 N--CA 1.419 -1.988 1 N-CA-C 95.4 -5.778 . . . . 0.0 95.4 167.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -64.8 150.55 74.48 Favored 'Cis proline' 0 CA--C 1.504 -1.006 0 CA-C-N 125.066 2.845 . . . . 0.0 109.736 -10.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.9 pt -134.3 137.25 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 1 N-CA-C 98.018 -4.808 . . . . 0.0 98.018 171.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 21.1 mt -171.41 -64.4 0.02 OUTLIER 'General case' 0 CA--C 1.488 -1.411 1 N-CA-C 97.783 -4.895 . . . . 0.0 97.783 -173.376 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.46 -101.32 0.43 Allowed 'General case' 0 N--CA 1.426 -1.649 1 N-CA-C 93.225 -6.583 . . . . 0.0 93.225 160.719 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -157.46 171.1 20.98 Favored 'General case' 0 CA--C 1.494 -1.204 1 N-CA-C 99.377 -4.305 . . . . 0.0 99.377 166.502 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -110.94 142.92 17.0 Favored Glycine 0 C--N 1.356 1.684 0 N-CA-C 104.054 -3.619 . . . . 0.0 104.054 173.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.6 mt -93.46 141.49 28.39 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-O 122.561 1.172 . . . . 0.0 111.425 -161.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m -90.34 152.28 21.09 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 126.084 1.754 . . . . 0.0 106.451 179.301 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -147.26 156.36 42.87 Favored 'General case' 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -154.99 161.29 41.42 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 94.8 -6.0 . . . . 0.0 94.8 172.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.945 0 O-C-N 124.164 0.915 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 . . . . . 0 N--CA 1.494 1.775 0 N-CA-C 105.631 -1.988 . . . . 0.0 105.631 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -166.55 -165.26 0.73 Allowed 'General case' 0 N--CA 1.434 -1.259 1 N-CA-C 96.613 -5.328 . . . . 0.0 96.613 -166.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.6 173.68 11.61 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 175.143 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.47 144.51 30.39 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 54.0 33.51 17.66 Favored 'General case' 0 CA--C 1.5 -0.966 0 C-N-CA 127.417 2.287 . . . . 0.0 112.346 -169.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p -147.4 170.59 17.04 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -179.26 178.47 0.7 Allowed 'General case' 0 N--CA 1.425 -1.715 1 N-CA-C 94.851 -5.981 . . . . 0.0 94.851 176.843 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.5 mt -149.74 166.42 15.27 Favored Pre-proline 0 CA--C 1.492 -1.273 1 N-CA-C 98.804 -4.517 . . . . 0.0 98.804 -171.725 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -71.24 -52.82 0.16 OUTLIER 'Cis proline' 0 CA--C 1.497 -1.365 0 CA-C-N 122.396 1.891 . . . . 0.0 109.851 -10.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.266 54.7 mt 80.63 -91.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 C-N-CA 127.979 2.512 . . . . 0.0 105.732 -175.023 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -144.65 175.03 10.46 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 96.142 -5.503 . . . . 0.0 96.142 175.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -78.1 74.83 4.64 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 119.061 0.846 . . . . 0.0 111.019 -170.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 74.1 m-80 -77.41 -87.61 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.212 0 C-N-CA 125.934 1.693 . . . . 0.0 106.708 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.47 -163.05 35.72 Favored Glycine 0 N--CA 1.42 -2.429 1 N-CA-C 98.414 -5.874 . . . . 0.0 98.414 174.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.4 mt -91.57 -155.15 0.39 Allowed 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m -89.83 153.33 20.74 Favored 'General case' 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 177.128 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.497 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.497 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -154.99 173.02 17.14 Favored 'General case' 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 84.3 mt -141.09 146.6 37.32 Favored 'General case' 0 N--CA 1.421 -1.893 1 N-CA-C 93.189 -6.596 . . . . 0.0 93.189 169.479 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.846 0 O-C-N 124.322 1.013 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 . . . . . 0 N--CA 1.448 -0.537 0 CA-C-O 121.223 0.535 . . . . 0.0 112.162 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m . . . . . 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p . . . . . 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm . . . . . 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 . . . . . 0 CA--C 1.502 -0.866 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p . . . . . 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 . . . . . 0 CA--C 1.5 -0.978 0 CA-C-O 120.777 0.323 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p . . . . . 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m . . . . . 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p . . . . . 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt . . . . . 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 . . . . . 0 CA--C 1.5 -0.952 0 CA-C-O 121.075 0.464 . . . . 0.0 111.633 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m . . . . . 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 . . . . . 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm . . . . . 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.442 -0.83 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m . . . . . 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 29' ' ' CYS . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p . . . . . 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt . . . . . 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 . . . . . 0 CA--C 1.505 -0.762 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p . . . . . 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m . . . . . 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt . . . . . 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 . . . . . 0 CA--C 1.505 -0.768 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m . . . . . 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp . . . . . 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 . . . . . 0 CA--C 1.505 -0.759 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p . . . . . 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm . . . . . 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m . . . . . 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.465 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.465 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt . . . . . 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 . . . . . 0 N--CA 1.442 -0.835 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p . . . . . 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m . . . . . 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 9' ' ' PHE . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm . . . . . 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 CA--C 1.502 -0.869 0 CA-C-O 120.513 0.197 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m . . . . . 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm . . . . . 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 . . . . . 0 CA--C 1.501 -0.924 0 CA-C-O 121.118 0.485 . . . . 0.0 111.516 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m . . . . . 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 . . . . . 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp . . . . . 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 . . . . . 0 N--CA 1.443 -0.797 0 CA-C-O 120.682 0.277 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p . . . . . 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 . . . . . 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p . . . . . 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm . . . . . 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 CA--C 1.503 -0.834 0 CA-C-O 120.764 0.316 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m . . . . . 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm . . . . . 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 . . . . . 0 CA--C 1.503 -0.844 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m . . . . . 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp . . . . . 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 . . . . . 0 N--CA 1.44 -0.938 0 CA-C-O 121.131 0.491 . . . . 0.0 111.94 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m . . . . . 0 N--CA 1.432 -1.37 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p . . . . . 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 . . . . . 0 CA--C 1.5 -0.966 0 CA-C-O 121.667 0.746 . . . . 0.0 112.346 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p . . . . . 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m . . . . . 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.497 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.497 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 . . . . . 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 38.8 t70 . . . . . 0 N--CA 1.494 1.748 0 N-CA-C 102.974 -2.973 . . . . 0.0 102.974 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -172.67 -170.68 0.71 Allowed 'General case' 0 N--CA 1.43 -1.442 1 N-CA-C 97.104 -5.147 . . . . 0.0 97.104 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 32.1 p -105.74 172.38 6.83 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 104.434 -2.432 . . . . 0.0 104.434 172.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 mt -103.17 149.62 7.19 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.257 0 N-CA-C 104.745 -2.317 . . . . 0.0 104.745 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -82.71 141.62 32.28 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.452 1.901 . . . . 0.0 109.061 -163.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.265 83.0 m-85 66.5 23.22 10.51 Favored 'General case' 0 C--N 1.357 0.933 0 C-N-CA 125.898 1.679 . . . . 0.0 112.162 -172.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.25 172.44 21.39 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 104.44 -3.464 . . . . 0.0 104.44 163.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -90.05 140.8 29.29 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -176.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -111.21 -123.31 0.27 Allowed 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 102.212 -3.255 . . . . 0.0 102.212 172.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.6 p -153.96 -160.2 1.07 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 102.754 -3.054 . . . . 0.0 102.754 173.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.7 mt -148.99 165.05 18.68 Favored Pre-proline 0 N--CA 1.43 -1.469 1 N-CA-C 97.491 -5.003 . . . . 0.0 97.491 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -64.01 144.5 55.77 Favored 'Cis proline' 0 CA--C 1.504 -0.986 0 CA-C-N 124.088 2.496 . . . . 0.0 109.74 -6.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -107.45 108.61 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.304 0 N-CA-C 105.372 -2.084 . . . . 0.0 105.372 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.2 mp -137.45 -63.13 0.6 Allowed 'General case' 0 CA--C 1.487 -1.448 1 N-CA-C 99.447 -4.279 . . . . 0.0 99.447 162.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.2 tmtm? -112.41 148.0 35.25 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 95.579 -5.711 . . . . 0.0 95.579 161.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -162.05 -166.66 1.47 Allowed 'General case' 0 N--CA 1.431 -1.408 1 N-CA-C 97.758 -4.904 . . . . 0.0 97.758 177.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -74.46 131.47 13.24 Favored Glycine 0 CA--C 1.493 -1.334 0 N-CA-C 105.849 -2.9 . . . . 0.0 105.849 173.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -88.33 133.45 34.07 Favored 'General case' 0 CA--C 1.491 -1.298 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -159.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 83.2 m -90.36 150.88 21.7 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -68.44 -28.8 67.38 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-N 118.347 0.521 . . . . 0.0 111.177 -178.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.4 p -90.29 4.8 49.65 Favored 'General case' 0 N--CA 1.444 -0.745 0 O-C-N 121.131 -0.981 . . . . 0.0 110.245 175.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.32 -58.36 1.16 Allowed Glycine 0 CA--C 1.489 -1.575 0 O-C-N 121.277 -0.889 . . . . 0.0 111.101 168.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.46 143.1 30.47 Favored 'General case' 0 CA--C 1.496 -1.096 0 CA-C-N 117.878 0.839 . . . . 0.0 109.102 -167.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 3.4 t -138.01 140.15 39.98 Favored 'General case' 0 N--CA 1.428 -1.572 1 N-CA-C 96.363 -5.421 . . . . 0.0 96.363 -178.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -160.32 60.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 101.572 -3.492 . . . . 0.0 101.572 170.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.83 -58.92 4.01 Favored Glycine 0 C--N 1.352 1.454 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -177.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -97.93 158.49 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.227 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 167.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 69.6 m -85.73 144.04 28.01 Favored 'General case' 0 CA--C 1.487 -1.469 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 172.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -150.37 -153.86 0.52 Allowed 'General case' 0 CA--C 1.489 -1.383 0 N-CA-C 103.67 -2.715 . . . . 0.0 103.67 -176.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -138.09 161.76 35.94 Favored 'General case' 0 N--CA 1.424 -1.761 1 N-CA-C 96.605 -5.331 . . . . 0.0 96.605 172.325 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 62.3 mt -153.59 167.59 29.03 Favored 'General case' 0 N--CA 1.424 -1.754 1 N-CA-C 94.934 -5.95 . . . . 0.0 94.934 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.955 0 O-C-N 124.225 0.953 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 . . . . . 0 N--CA 1.495 1.796 0 N-CA-C 102.041 -3.318 . . . . 0.0 102.041 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -143.61 159.09 43.08 Favored 'General case' 0 N--CA 1.427 -1.601 1 N-CA-C 95.389 -5.782 . . . . 0.0 95.389 175.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.7 p -176.46 -177.88 0.88 Allowed 'General case' 0 N--CA 1.42 -1.946 1 N-CA-C 97.031 -5.174 . . . . 0.0 97.031 -178.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.6 mt -98.77 153.3 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 104.516 -2.402 . . . . 0.0 104.516 170.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -75.29 140.35 43.08 Favored 'General case' 0 N--CA 1.435 -1.204 0 C-N-CA 127.159 2.184 . . . . 0.0 107.913 -168.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.302 78.8 m-85 64.39 30.19 13.26 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 127.933 2.493 . . . . 0.0 112.675 -171.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.33 174.03 20.91 Favored Glycine 0 C--N 1.351 1.395 0 N-CA-C 105.239 -3.145 . . . . 0.0 105.239 163.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.1 m-85 -84.55 133.97 34.43 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 -175.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.2 p -120.46 -18.02 7.98 Favored 'General case' 0 CA--C 1.493 -1.239 0 CA-C-N 117.95 0.341 . . . . 0.0 110.874 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -74.09 -69.8 0.42 Allowed 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -160.14 164.39 19.95 Favored Pre-proline 0 N--CA 1.421 -1.898 1 N-CA-C 97.704 -4.925 . . . . 0.0 97.704 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -68.09 167.06 65.46 Favored 'Cis proline' 0 CA--C 1.5 -1.184 0 CA-C-N 124.683 2.708 . . . . 0.0 110.459 -1.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.408 HG22 ' H ' ' A' ' 14' ' ' ILE . 3.3 tp -75.44 97.18 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.184 0 CA-C-O 122.371 1.082 . . . . 0.0 108.09 178.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -109.56 -53.68 2.63 Favored 'General case' 0 CA--C 1.483 -1.634 0 N-CA-C 102.527 -3.138 . . . . 0.0 102.527 163.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mtpp -138.63 160.9 38.48 Favored 'General case' 0 N--CA 1.418 -2.074 1 N-CA-C 94.906 -5.961 . . . . 0.0 94.906 153.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -123.19 145.49 48.59 Favored 'General case' 0 CA--C 1.492 -1.275 1 N-CA-C 97.966 -4.827 . . . . 0.0 97.966 168.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 122.15 -134.75 9.95 Favored Glycine 0 C--N 1.35 1.352 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 169.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 45.3 tp -73.57 127.88 33.95 Favored 'General case' 0 C--N 1.36 1.056 0 C-N-CA 125.815 1.646 . . . . 0.0 113.036 -159.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.8 m -90.26 148.01 23.17 Favored 'General case' 0 CA--C 1.493 -1.24 0 C-N-CA 124.738 1.215 . . . . 0.0 108.407 174.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.06 -33.0 74.56 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.613 0.642 . . . . 0.0 111.146 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.2 p -90.25 12.71 17.3 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.373 0.669 . . . . 0.0 110.067 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.87 -67.46 1.82 Allowed Glycine 0 CA--C 1.489 -1.534 0 O-C-N 121.13 -0.981 . . . . 0.0 112.116 164.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.32 137.95 33.16 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-N 117.948 0.874 . . . . 0.0 109.677 -163.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.8 t -119.68 127.6 53.04 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 100.741 -3.8 . . . . 0.0 100.741 177.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.6 p -145.03 54.79 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.972 0 N-CA-C 101.879 -3.378 . . . . 0.0 101.879 175.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.53 -65.66 1.24 Allowed Glycine 0 CA--C 1.491 -1.428 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 m -95.01 160.79 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.409 0 N-CA-C 105.206 -2.146 . . . . 0.0 105.206 171.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.5 m -78.84 126.45 30.72 Favored 'General case' 0 CA--C 1.485 -1.535 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 172.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.84 -153.26 0.56 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -139.72 171.01 14.85 Favored 'General case' 0 N--CA 1.424 -1.759 1 N-CA-C 96.983 -5.191 . . . . 0.0 96.983 172.726 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.8 mt -147.71 156.24 42.55 Favored 'General case' 0 N--CA 1.422 -1.833 1 N-CA-C 93.89 -6.337 . . . . 0.0 93.89 173.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.838 0 O-C-N 124.507 1.129 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.0 t70 . . . . . 0 N--CA 1.487 1.386 0 N-CA-C 102.585 -3.117 . . . . 0.0 102.585 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 61.9 t0 -97.29 -71.99 0.66 Allowed 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 104.816 -2.29 . . . . 0.0 104.816 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 21.6 p -146.73 172.43 13.64 Favored 'General case' 0 N--CA 1.426 -1.642 1 N-CA-C 99.453 -4.277 . . . . 0.0 99.453 173.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.9 mt -92.54 146.0 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 103.746 -2.687 . . . . 0.0 103.746 175.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -86.39 135.88 33.34 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 -172.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 79.69 1.78 2.17 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 127.119 2.168 . . . . 0.0 110.463 -176.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -86.84 172.48 44.18 Favored Glycine 0 C--N 1.35 1.315 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 166.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -82.5 147.49 28.66 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.0 p -99.51 91.67 5.02 Favored 'General case' 0 CA--C 1.498 -1.046 0 CA-C-O 122.348 1.07 . . . . 0.0 108.447 -178.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.02 162.08 25.06 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 175.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 96.4 mt -137.46 159.99 67.16 Favored Pre-proline 0 N--CA 1.435 -1.179 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 170.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -64.65 148.66 71.43 Favored 'Cis proline' 0 CA--C 1.506 -0.913 0 CA-C-N 126.78 3.457 . . . . 0.0 114.224 14.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.9 tt -72.1 -24.45 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.743 0 C-N-CA 125.553 1.541 . . . . 0.0 110.863 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 70.4 mt -75.03 -32.5 61.6 Favored 'General case' 0 CA--C 1.5 -0.953 0 O-C-N 121.38 -0.825 . . . . 0.0 109.979 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.1 mmtp -82.9 -53.0 6.19 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 36.4 m-80 -89.57 -109.63 0.08 Allowed 'General case' 0 N--CA 1.442 -0.826 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 -170.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 166.16 -151.89 20.62 Favored Glycine 0 CA--C 1.474 -2.502 1 N-CA-C 99.303 -5.519 . . . . 0.0 99.303 175.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 82.2 mt -113.76 177.45 4.63 Favored 'General case' 0 N--CA 1.432 -1.341 0 N-CA-C 102.182 -3.266 . . . . 0.0 102.182 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 68.2 m -89.06 141.61 28.35 Favored 'General case' 0 CA--C 1.495 -1.146 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 -176.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.86 -20.9 62.48 Favored 'General case' 0 C--N 1.353 0.731 0 CA-C-N 118.978 0.808 . . . . 0.0 111.032 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 18.6 p -87.25 2.56 49.75 Favored 'General case' 0 N--CA 1.445 -0.703 0 O-C-N 121.032 -1.043 . . . . 0.0 110.771 171.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.5 -76.96 0.32 Allowed Glycine 0 CA--C 1.494 -1.267 0 O-C-N 120.972 -1.08 . . . . 0.0 110.856 173.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.57 137.85 33.07 Favored 'General case' 0 CA--C 1.495 -1.14 0 O-C-N 121.732 -0.863 . . . . 0.0 112.29 -159.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.7 t -102.54 120.55 40.73 Favored 'General case' 0 CA--C 1.491 -1.304 0 N-CA-C 101.305 -3.591 . . . . 0.0 101.305 170.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.1 p -144.99 48.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 N-CA-C 102.97 -2.974 . . . . 0.0 102.97 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.54 -61.75 4.12 Favored Glycine 0 C--N 1.353 1.487 0 N-CA-C 106.616 -2.594 . . . . 0.0 106.616 -174.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.0 m -94.85 166.32 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.547 -2.02 . . . . 0.0 105.547 168.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 12.3 m -83.83 119.25 24.62 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 170.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -143.94 -143.7 0.15 Allowed 'General case' 0 N--CA 1.433 -1.29 0 N-CA-C 103.965 -2.606 . . . . 0.0 103.965 -178.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -142.54 170.25 16.05 Favored 'General case' 0 N--CA 1.427 -1.614 1 N-CA-C 98.641 -4.577 . . . . 0.0 98.641 -175.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.9 mt -147.77 167.82 23.72 Favored 'General case' 0 N--CA 1.423 -1.808 1 N-CA-C 94.345 -6.169 . . . . 0.0 94.345 174.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.869 0 O-C-N 124.351 1.032 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 . . . . . 0 N--CA 1.505 2.296 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -82.89 -170.15 2.86 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 103.897 -2.631 . . . . 0.0 103.897 151.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.7 p -148.39 -169.26 3.31 Favored 'General case' 0 CA--C 1.488 -1.425 0 N-CA-C 101.01 -3.7 . . . . 0.0 101.01 178.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.436 HD11 HD22 ' A' ' 17' ' ' ASN . 13.8 mt -116.96 154.65 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 104.405 -2.443 . . . . 0.0 104.405 176.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -81.66 140.98 34.05 Favored 'General case' 0 N--CA 1.437 -1.117 0 C-N-CA 128.194 2.598 . . . . 0.0 109.172 -161.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 64.12 28.1 14.13 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 126.184 1.794 . . . . 0.0 111.633 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.36 174.04 29.29 Favored Glycine 0 C--N 1.35 1.328 0 N-CA-C 105.704 -2.958 . . . . 0.0 105.704 165.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.1 t80 -87.65 144.6 26.58 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 105.077 -2.194 . . . . 0.0 105.077 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -119.95 123.43 43.51 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -133.58 159.19 41.19 Favored 'General case' 0 N--CA 1.431 -1.398 1 N-CA-C 94.649 -6.056 . . . . 0.0 94.649 161.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 pp -155.42 160.76 30.6 Favored Pre-proline 0 N--CA 1.425 -1.677 0 N-CA-C 101.124 -3.658 . . . . 0.0 101.124 178.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -70.66 167.87 72.39 Favored 'Cis proline' 0 N--CA 1.453 -0.887 0 N-CA-C 108.92 -1.223 . . . . 0.0 108.92 -23.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tt -150.03 -46.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 N-CA-C 102.502 -3.147 . . . . 0.0 102.502 178.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 86.7 mt -117.33 -151.73 0.49 Allowed 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 101.726 -3.435 . . . . 0.0 101.726 167.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.4 mptp? -91.81 59.96 3.8 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 170.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.436 HD22 HD11 ' A' ' 4' ' ' ILE . 6.0 p-10 -83.84 -122.71 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 124.921 1.288 . . . . 0.0 108.579 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 150.67 -144.15 11.48 Favored Glycine 0 CA--C 1.475 -2.439 1 N-CA-C 98.677 -5.769 . . . . 0.0 98.677 -174.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.7 mt -84.64 -167.09 1.66 Allowed 'General case' 0 N--CA 1.438 -1.061 0 O-C-N 125.116 1.127 . . . . 0.0 108.435 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.5 m -90.39 150.29 21.92 Favored 'General case' 0 N--CA 1.432 -1.351 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -173.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -70.28 -22.95 62.8 Favored 'General case' 0 C--N 1.351 0.672 0 O-C-N 121.977 -0.452 . . . . 0.0 110.929 -177.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.7 p -88.26 -9.05 54.17 Favored 'General case' 0 N--CA 1.444 -0.759 0 O-C-N 121.27 -0.894 . . . . 0.0 109.842 175.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 124.98 -90.38 0.4 Allowed Glycine 0 CA--C 1.486 -1.775 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 172.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.37 155.75 24.56 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-O 121.263 0.554 . . . . 0.0 110.638 -160.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 4.1 t -126.78 130.48 50.37 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 98.604 -4.591 . . . . 0.0 98.604 177.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 p -150.59 49.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 N-CA-C 101.883 -3.377 . . . . 0.0 101.883 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.76 -59.09 1.25 Allowed Glycine 0 C--N 1.352 1.469 0 N-CA-C 106.73 -2.548 . . . . 0.0 106.73 -179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 m -101.98 165.43 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 104.195 -2.52 . . . . 0.0 104.195 165.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 65.4 m -82.26 136.28 35.09 Favored 'General case' 0 CA--C 1.483 -1.605 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 175.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.32 -162.36 1.19 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 104.401 -2.444 . . . . 0.0 104.401 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -109.98 -179.61 3.84 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 104.64 -2.355 . . . . 0.0 104.64 178.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 tp -162.1 164.34 28.1 Favored 'General case' 0 N--CA 1.421 -1.894 1 N-CA-C 96.111 -5.515 . . . . 0.0 96.111 -177.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.027 0 O-C-N 124.226 0.954 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 101.881 -3.377 . . . . 0.0 101.881 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.96 -24.77 59.68 Favored 'General case' 0 C--N 1.352 0.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.26 176.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -138.81 -167.86 2.29 Favored 'General case' 0 N--CA 1.43 -1.467 1 N-CA-C 99.106 -4.405 . . . . 0.0 99.106 173.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.2 mm -90.23 140.8 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 N-CA-C 102.57 -3.122 . . . . 0.0 102.57 162.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -73.69 143.2 46.3 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 124.932 1.293 . . . . 0.0 108.066 -166.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 65.67 27.98 11.23 Favored 'General case' 0 N--CA 1.442 -0.83 0 C-N-CA 126.69 1.996 . . . . 0.0 112.153 -173.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -107.18 168.47 14.24 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 104.241 -3.544 . . . . 0.0 104.241 164.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -87.81 150.01 23.81 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.4 p -113.83 151.93 31.4 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 175.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.91 159.68 21.26 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 105.478 -2.045 . . . . 0.0 105.478 165.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 16.0 mt -156.67 165.15 19.36 Favored Pre-proline 0 N--CA 1.434 -1.25 1 N-CA-C 97.668 -4.938 . . . . 0.0 97.668 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -69.72 -77.24 0.0 OUTLIER 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 125.13 2.868 . . . . 0.0 110.988 -2.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 tp -129.0 121.33 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.741 1 N-CA-C 97.583 -4.969 . . . . 0.0 97.583 167.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.6 mt -140.44 -98.19 0.15 Allowed 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 101.248 -3.612 . . . . 0.0 101.248 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -129.23 130.38 46.19 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 96.512 -5.366 . . . . 0.0 96.512 157.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 177.19 -173.35 0.11 Allowed 'General case' 0 N--CA 1.426 -1.671 1 N-CA-C 97.209 -5.108 . . . . 0.0 97.209 -168.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 177.69 -170.53 42.94 Favored Glycine 0 N--CA 1.424 -2.166 1 N-CA-C 97.314 -6.314 . . . . 0.0 97.314 -177.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.2 mp -83.13 172.13 12.99 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 177.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.3 m -90.29 163.4 14.77 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 175.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 8.2 m -68.75 -31.91 71.3 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-N 118.849 0.749 . . . . 0.0 109.496 178.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.41 8.31 31.48 Favored 'General case' 0 N--CA 1.435 -1.205 0 C-N-CA 124.565 1.146 . . . . 0.0 109.928 176.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.5 -82.37 0.51 Allowed Glycine 0 C--N 1.351 1.388 0 O-C-N 121.08 -1.013 . . . . 0.0 110.919 172.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.38 156.46 18.22 Favored 'General case' 0 CA--C 1.489 -1.369 0 CA-C-N 117.303 0.551 . . . . 0.0 109.795 -156.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 29' ' ' CYS . 15.3 t -136.61 142.97 43.31 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 102.277 -3.231 . . . . 0.0 102.277 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 p -142.27 60.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 100.799 -3.778 . . . . 0.0 100.799 174.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.42 -61.03 3.61 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 106.964 -2.455 . . . . 0.0 106.964 -176.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.6 m -98.11 150.45 4.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.143 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 168.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 56.3 m -73.44 139.35 45.77 Favored 'General case' 0 CA--C 1.486 -1.495 0 C-N-CA 123.668 0.787 . . . . 0.0 109.62 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.16 -145.25 0.17 Allowed 'General case' 0 N--CA 1.427 -1.576 0 N-CA-C 103.215 -2.884 . . . . 0.0 103.215 -178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -141.4 174.53 10.46 Favored 'General case' 0 N--CA 1.426 -1.656 1 N-CA-C 99.398 -4.297 . . . . 0.0 99.398 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -83.59 71.93 10.33 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.167 0 CA-C-N 116.383 -0.371 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 . . . . . 0 N--CA 1.493 1.682 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -89.8 -165.35 1.33 Allowed 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 103.822 -2.658 . . . . 0.0 103.822 157.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.2 p -151.91 -176.07 5.49 Favored 'General case' 0 N--CA 1.43 -1.464 1 N-CA-C 99.464 -4.273 . . . . 0.0 99.464 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.3 mm -108.48 153.35 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.337 0 N-CA-C 103.863 -2.643 . . . . 0.0 103.863 171.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.0 tptt -78.76 144.45 35.18 Favored 'General case' 0 N--CA 1.437 -1.082 0 C-N-CA 127.578 2.351 . . . . 0.0 107.762 -173.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.253 80.3 m-85 70.82 18.58 6.12 Favored 'General case' 0 C--N 1.356 0.865 0 C-N-CA 126.572 1.949 . . . . 0.0 112.397 -175.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.9 171.32 22.55 Favored Glycine 0 C--N 1.351 1.411 0 N-CA-C 105.647 -2.981 . . . . 0.0 105.647 167.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -87.72 133.44 33.85 Favored 'General case' 0 CA--C 1.504 -0.808 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -176.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.8 p -106.14 164.69 11.79 Favored 'General case' 0 CA--C 1.493 -1.248 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -173.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.8 p -164.09 -125.24 0.02 OUTLIER 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 -166.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 95.7 mt -155.58 171.1 7.7 Favored Pre-proline 0 N--CA 1.425 -1.687 1 N-CA-C 98.593 -4.595 . . . . 0.0 98.593 -161.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_exo -64.56 135.27 21.38 Favored 'Cis proline' 0 CA--C 1.504 -0.988 0 CA-C-N 123.093 2.14 . . . . 0.0 109.922 -16.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.8 pt -73.04 155.73 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.068 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 53.4 mt 79.08 -35.47 0.16 Allowed 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 126.187 1.795 . . . . 0.0 110.717 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt -76.39 -62.43 1.62 Allowed 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 5.8 p-10 -133.85 -129.63 0.17 Allowed 'General case' 0 N--CA 1.437 -1.113 0 N-CA-C 100.631 -3.84 . . . . 0.0 100.631 173.369 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 84.52 -58.59 4.98 Favored Glycine 0 CA--C 1.487 -1.676 0 N-CA-C 110.326 -1.11 . . . . 0.0 110.326 168.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 83.2 mt -81.98 149.31 28.22 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -177.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.8 m -90.54 151.89 21.15 Favored 'General case' 0 CA--C 1.488 -1.437 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 -174.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.4 m -71.03 -26.41 63.09 Favored 'General case' 0 C--N 1.35 0.601 0 O-C-N 121.821 -0.55 . . . . 0.0 110.586 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.3 p -90.34 11.96 19.79 Favored 'General case' 0 N--CA 1.441 -0.911 0 O-C-N 121.177 -0.952 . . . . 0.0 110.576 172.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.37 -66.18 2.09 Favored Glycine 0 CA--C 1.491 -1.467 0 O-C-N 121.158 -0.964 . . . . 0.0 111.576 167.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.47 133.87 35.21 Favored 'General case' 0 CA--C 1.494 -1.193 0 CA-C-N 117.943 0.872 . . . . 0.0 108.85 -164.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.6 t -128.97 125.95 38.53 Favored 'General case' 0 CA--C 1.487 -1.45 1 N-CA-C 99.061 -4.422 . . . . 0.0 99.061 -178.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.9 p -151.36 56.57 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 101.917 -3.364 . . . . 0.0 101.917 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.77 -64.94 2.73 Favored Glycine 0 C--N 1.351 1.372 0 N-CA-C 106.318 -2.713 . . . . 0.0 106.318 -176.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -94.61 162.82 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.145 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 168.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 94.3 m -83.87 139.73 32.44 Favored 'General case' 0 CA--C 1.484 -1.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 168.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.12 -153.37 0.47 Allowed 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 102.663 -3.088 . . . . 0.0 102.663 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.42 173.65 7.02 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 102.352 -3.203 . . . . 0.0 102.352 175.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.2 mp -84.43 68.2 10.17 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 -172.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.174 0 CA-C-N 116.499 -0.319 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.497 1.906 0 N-CA-C 104.118 -2.549 . . . . 0.0 104.118 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -158.42 179.52 9.06 Favored 'General case' 0 N--CA 1.43 -1.451 1 N-CA-C 96.778 -5.267 . . . . 0.0 96.778 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.34 160.59 34.56 Favored 'General case' 0 CA--C 1.489 -1.371 1 N-CA-C 98.245 -4.724 . . . . 0.0 98.245 168.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.0 mt -94.55 146.01 7.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.121 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 -172.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 79.8 tttt -65.87 138.92 58.2 Favored 'General case' 0 N--CA 1.444 -0.73 0 C-N-CA 128.65 2.78 . . . . 0.0 110.578 -166.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 68.12 20.76 8.88 Favored 'General case' 0 C--N 1.355 0.824 0 C-N-CA 125.531 1.532 . . . . 0.0 112.175 -175.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.06 172.05 27.69 Favored Glycine 0 C--N 1.35 1.323 0 N-CA-C 104.534 -3.426 . . . . 0.0 104.534 163.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -87.17 142.12 28.14 Favored 'General case' 0 CA--C 1.492 -1.282 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.6 -115.0 0.3 Allowed 'General case' 0 N--CA 1.434 -1.253 0 N-CA-C 101.981 -3.34 . . . . 0.0 101.981 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.4 p -167.15 -163.3 0.52 Allowed 'General case' 0 N--CA 1.427 -1.599 1 N-CA-C 98.046 -4.798 . . . . 0.0 98.046 179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 19.0 mt -150.42 167.76 12.35 Favored Pre-proline 0 N--CA 1.429 -1.496 1 N-CA-C 97.512 -4.996 . . . . 0.0 97.512 176.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -66.99 151.96 83.43 Favored 'Cis proline' 0 CA--C 1.504 -1.004 0 CA-C-N 122.988 2.103 . . . . 0.0 109.992 -9.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.2 tp -99.9 102.05 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 105.862 -1.903 . . . . 0.0 105.862 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 99.4 mt -124.72 -79.08 0.61 Allowed 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 100.659 -3.83 . . . . 0.0 100.659 165.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.7 mttp -132.03 145.33 51.37 Favored 'General case' 0 N--CA 1.424 -1.747 1 N-CA-C 95.213 -5.847 . . . . 0.0 95.213 154.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -160.36 -50.06 0.05 OUTLIER 'General case' 0 CA--C 1.487 -1.467 0 N-CA-C 100.855 -3.757 . . . . 0.0 100.855 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -141.5 -172.42 13.27 Favored Glycine 0 N--CA 1.427 -1.926 1 N-CA-C 98.6 -5.8 . . . . 0.0 98.6 162.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.4 tp -137.33 131.95 32.91 Favored 'General case' 0 CA--C 1.483 -1.63 1 N-CA-C 99.285 -4.339 . . . . 0.0 99.285 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 84.2 m -90.71 150.11 21.77 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.9 m -70.33 -33.96 72.11 Favored 'General case' 0 C--N 1.35 0.59 0 O-C-N 121.915 -0.491 . . . . 0.0 110.57 -173.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.34 11.57 20.98 Favored 'General case' 0 N--CA 1.44 -0.937 0 C-N-CA 124.132 0.973 . . . . 0.0 110.822 177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.89 -63.59 0.65 Allowed Glycine 0 CA--C 1.489 -1.588 0 O-C-N 121.237 -0.915 . . . . 0.0 111.318 168.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.49 149.09 25.22 Favored 'General case' 0 CA--C 1.496 -1.113 0 CA-C-N 118.399 1.1 . . . . 0.0 109.413 -166.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -139.55 139.05 36.76 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 97.256 -5.09 . . . . 0.0 97.256 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 p -160.03 58.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 N-CA-C 102.852 -3.018 . . . . 0.0 102.852 172.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.65 -58.65 3.72 Favored Glycine 0 C--N 1.352 1.444 0 N-CA-C 107.46 -2.256 . . . . 0.0 107.46 -176.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 m -97.87 159.36 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.138 0 N-CA-C 104.99 -2.226 . . . . 0.0 104.99 167.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.1 m -83.01 142.47 31.32 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.65 -150.09 0.3 Allowed 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.13 164.5 30.5 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 98.452 -4.647 . . . . 0.0 98.452 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -85.87 66.91 9.84 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 -173.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.128 0 CA-C-N 116.587 -0.279 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 100.917 -3.734 . . . . 0.0 100.917 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.79 -77.75 0.36 Allowed 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.793 -1.929 . . . . 0.0 105.793 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -140.17 170.76 15.23 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 101.268 -3.604 . . . . 0.0 101.268 176.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.2 mt -100.3 151.35 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 102.735 -3.061 . . . . 0.0 102.735 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.7 ttpp -79.5 137.57 37.25 Favored 'General case' 0 N--CA 1.438 -1.054 0 C-N-CA 126.125 1.77 . . . . 0.0 108.911 -163.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 70.22 19.88 6.45 Favored 'General case' 0 C--N 1.355 0.837 0 C-N-CA 127.345 2.258 . . . . 0.0 112.585 -174.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.16 168.84 21.33 Favored Glycine 0 CA--C 1.49 -1.482 0 N-CA-C 105.29 -3.124 . . . . 0.0 105.29 166.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -77.07 154.43 33.36 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 179.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 13.3 p -137.15 170.27 16.38 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -169.21 174.64 6.05 Favored 'General case' 0 N--CA 1.424 -1.751 1 N-CA-C 98.008 -4.812 . . . . 0.0 98.008 -163.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -143.81 162.04 43.13 Favored Pre-proline 0 N--CA 1.433 -1.318 1 N-CA-C 97.841 -4.874 . . . . 0.0 97.841 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -63.07 145.28 53.31 Favored 'Cis proline' 0 CA--C 1.503 -1.049 0 CA-C-N 126.154 3.233 . . . . 0.0 115.328 17.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.3 tt -69.83 149.18 10.81 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.941 0 C-N-CA 125.404 1.481 . . . . 0.0 108.195 -174.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 67.5 mt 75.19 -48.58 0.63 Allowed 'General case' 0 C--N 1.356 0.885 0 C-N-CA 127.607 2.363 . . . . 0.0 111.172 178.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -64.69 -44.79 89.16 Favored 'General case' 0 CA--C 1.504 -0.824 0 C-N-CA 125.429 1.491 . . . . 0.0 107.743 177.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -80.5 -70.07 0.55 Allowed 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 166.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.26 -143.49 8.6 Favored Glycine 0 N--CA 1.422 -2.264 1 N-CA-C 98.706 -5.758 . . . . 0.0 98.706 172.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -152.46 -179.63 7.74 Favored 'General case' 0 N--CA 1.426 -1.661 1 N-CA-C 95.255 -5.831 . . . . 0.0 95.255 161.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.2 m -89.47 143.88 26.47 Favored 'General case' 0 CA--C 1.489 -1.372 0 CA-C-N 120.439 1.472 . . . . 0.0 107.388 -173.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -69.72 -29.81 67.3 Favored 'General case' 0 C--N 1.353 0.761 0 O-C-N 121.828 -0.545 . . . . 0.0 109.779 -178.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -88.18 7.6 31.08 Favored 'General case' 0 N--CA 1.433 -1.296 0 C-N-CA 123.89 0.876 . . . . 0.0 110.01 175.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 105.4 -78.09 0.26 Allowed Glycine 0 CA--C 1.487 -1.687 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -87.22 139.65 30.35 Favored 'General case' 0 CA--C 1.496 -1.133 0 O-C-N 122.379 -0.483 . . . . 0.0 110.102 -160.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.7 t -120.89 123.49 42.64 Favored 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -115.71 -130.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.92 1 N-CA-C 97.995 -4.817 . . . . 0.0 97.995 164.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.48 -7.83 85.55 Favored Glycine 0 C--N 1.351 1.364 0 O-C-N 117.99 -2.944 . . . . 0.0 110.682 176.245 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 m -141.57 166.03 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.735 0 N-CA-C 101.203 -3.629 . . . . 0.0 101.203 -175.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 60.0 m -85.49 128.78 34.85 Favored 'General case' 0 CA--C 1.481 -1.682 0 O-C-N 124.912 1.383 . . . . 0.0 107.543 172.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.44 -154.75 0.63 Allowed 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.728 -2.693 . . . . 0.0 103.728 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -124.88 -163.59 1.2 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 102.465 -3.161 . . . . 0.0 102.465 177.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.6 tp -135.02 143.16 46.62 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 94.357 -6.164 . . . . 0.0 94.357 172.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.271 0.982 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.1 m-20 . . . . . 0 N--CA 1.498 1.968 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -148.38 161.76 40.94 Favored 'General case' 0 N--CA 1.431 -1.404 1 N-CA-C 94.961 -5.94 . . . . 0.0 94.961 171.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 4.3 p -153.51 163.75 39.41 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 101.848 -3.39 . . . . 0.0 101.848 -178.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 15.6 mm -92.3 148.58 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.145 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -178.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -74.89 143.97 43.56 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 126.791 2.036 . . . . 0.0 108.807 -170.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.259 75.9 m-85 70.3 22.55 5.37 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 126.487 1.915 . . . . 0.0 113.003 -176.096 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.39 166.43 19.74 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 103.862 -3.695 . . . . 0.0 103.862 161.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -84.67 140.46 31.3 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.6 p -107.03 176.59 5.12 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.7 p -151.04 168.21 25.31 Favored 'General case' 0 N--CA 1.419 -1.983 1 N-CA-C 98.765 -4.532 . . . . 0.0 98.765 -173.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 92.3 mt -144.12 157.16 57.62 Favored Pre-proline 0 N--CA 1.425 -1.722 1 N-CA-C 95.497 -5.742 . . . . 0.0 95.497 175.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.13 164.22 74.68 Favored 'Cis proline' 0 CA--C 1.503 -1.05 0 CA-C-N 124.764 2.737 . . . . 0.0 110.582 5.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -85.36 119.48 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.286 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.3 mt -137.0 -77.09 0.41 Allowed 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 103.902 -2.629 . . . . 0.0 103.902 174.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.7 mtpt -134.12 47.5 2.41 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 -178.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 176.91 175.41 0.37 Allowed 'General case' 0 N--CA 1.427 -1.615 1 N-CA-C 96.465 -5.383 . . . . 0.0 96.465 -164.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.04 -51.53 0.69 Allowed Glycine 0 CA--C 1.484 -1.89 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 173.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.0 mt -80.63 130.95 35.41 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.4 m -90.7 147.15 23.45 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 105.503 -2.036 . . . . 0.0 105.503 167.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.0 m -69.19 -30.04 68.16 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 118.269 0.486 . . . . 0.0 110.737 -174.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.0 p -90.41 9.54 28.69 Favored 'General case' 0 N--CA 1.442 -0.828 0 C-N-CA 124.182 0.993 . . . . 0.0 111.514 174.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.6 -70.82 0.38 Allowed Glycine 0 CA--C 1.492 -1.403 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 171.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.6 136.09 35.55 Favored 'General case' 0 CA--C 1.5 -0.957 0 O-C-N 121.908 -0.76 . . . . 0.0 110.646 -165.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 9.1 t -120.01 124.66 46.45 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 99.079 -4.415 . . . . 0.0 99.079 177.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.7 p -144.53 44.39 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 N-CA-C 102.938 -2.986 . . . . 0.0 102.938 -176.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.1 -63.3 2.09 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 106.009 -2.836 . . . . 0.0 106.009 -175.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.5 m -90.88 163.06 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 N-CA-C 105.069 -2.197 . . . . 0.0 105.069 164.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 82.8 m -83.64 144.21 29.58 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 168.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.58 -151.87 0.4 Allowed 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 103.125 -2.917 . . . . 0.0 103.125 179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -143.85 156.35 44.43 Favored 'General case' 0 N--CA 1.425 -1.72 1 N-CA-C 96.222 -5.473 . . . . 0.0 96.222 170.726 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 44.8 mt -155.63 163.89 39.33 Favored 'General case' 0 N--CA 1.423 -1.777 1 N-CA-C 94.554 -6.091 . . . . 0.0 94.554 176.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.234 0.959 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 102.532 -3.136 . . . . 0.0 102.532 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.6 t70 69.66 -103.69 0.05 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 125.557 1.543 . . . . 0.0 108.402 -175.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 17.3 p -134.4 168.43 18.93 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 104.491 -2.411 . . . . 0.0 104.491 174.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 mt -109.99 156.05 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 102.726 -3.065 . . . . 0.0 102.726 179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.0 ttmm -89.78 141.38 28.68 Favored 'General case' 0 N--CA 1.433 -1.295 0 C-N-CA 126.565 1.946 . . . . 0.0 109.032 -158.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.282 84.1 m-85 65.32 25.98 12.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 C-N-CA 127.431 2.292 . . . . 0.0 112.891 -174.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.13 170.96 23.03 Favored Glycine 0 N--CA 1.436 -1.317 0 N-CA-C 105.171 -3.172 . . . . 0.0 105.171 162.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -77.52 149.67 34.91 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -146.61 -177.65 5.75 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 100.593 -3.854 . . . . 0.0 100.593 174.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 p -167.44 176.91 6.29 Favored 'General case' 0 N--CA 1.417 -2.096 1 N-CA-C 99.874 -4.121 . . . . 0.0 99.874 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -139.89 157.72 69.0 Favored Pre-proline 0 N--CA 1.424 -1.733 1 N-CA-C 94.366 -6.161 . . . . 0.0 94.366 160.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -68.31 172.54 42.61 Favored 'Cis proline' 0 C--N 1.319 -1.023 0 CA-C-N 124.461 2.629 . . . . 0.0 110.941 -8.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.487 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.0 OUTLIER -77.84 121.59 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 C-N-CA 125.388 1.475 . . . . 0.0 109.626 -170.731 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mp -108.92 -64.0 1.29 Allowed 'General case' 0 CA--C 1.495 -1.157 0 N-CA-C 103.694 -2.706 . . . . 0.0 103.694 172.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -152.24 42.01 0.65 Allowed 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 103.167 -2.901 . . . . 0.0 103.167 -177.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -90.49 -144.37 0.17 Allowed 'General case' 0 CA--C 1.5 -0.972 0 C-N-CA 125.229 1.412 . . . . 0.0 107.349 -164.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.19 -165.61 38.7 Favored Glycine 0 N--CA 1.421 -2.312 1 N-CA-C 97.218 -6.353 . . . . 0.0 97.218 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -86.45 174.31 9.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 170.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 78.3 m -90.31 140.3 29.83 Favored 'General case' 0 CA--C 1.488 -1.419 0 N-CA-C 103.964 -2.606 . . . . 0.0 103.964 166.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -71.39 -23.77 61.94 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.112 0.869 . . . . 0.0 110.306 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.3 p -89.96 -4.05 57.69 Favored 'General case' 0 N--CA 1.436 -1.156 0 O-C-N 121.639 -0.663 . . . . 0.0 109.785 178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 112.67 -70.2 0.22 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 169.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.89 139.54 37.09 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 117.717 0.759 . . . . 0.0 109.975 -164.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 t -130.54 128.26 40.76 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 100.954 -3.721 . . . . 0.0 100.954 177.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.5 p -130.04 -132.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.119 1 N-CA-C 96.51 -5.367 . . . . 0.0 96.51 164.514 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.465 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -74.39 -6.11 74.64 Favored Glycine 0 C--N 1.345 1.052 0 O-C-N 118.213 -2.804 . . . . 0.0 111.668 176.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 m -142.87 159.1 18.34 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.578 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 -175.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 70.8 m -86.88 134.2 33.55 Favored 'General case' 0 CA--C 1.492 -1.278 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 173.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.4 -162.77 1.28 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.468 -2.049 . . . . 0.0 105.468 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.63 171.84 11.29 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -173.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 23.0 mt -155.08 167.73 29.38 Favored 'General case' 0 N--CA 1.424 -1.737 1 N-CA-C 95.285 -5.82 . . . . 0.0 95.285 -176.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.359 0.994 0 O-C-N 123.894 0.746 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.498 1.945 0 N-CA-C 104.882 -2.266 . . . . 0.0 104.882 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.2 m-20 -154.47 -177.44 6.47 Favored 'General case' 0 N--CA 1.431 -1.383 1 N-CA-C 96.183 -5.488 . . . . 0.0 96.183 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.8 p -161.91 -175.94 4.94 Favored 'General case' 0 N--CA 1.425 -1.68 1 N-CA-C 97.475 -5.009 . . . . 0.0 97.475 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.4 mt -96.93 149.32 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.041 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 164.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -76.16 144.06 40.77 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 127.045 2.138 . . . . 0.0 108.478 -164.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 70.58 20.55 5.77 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 127.753 2.421 . . . . 0.0 111.851 -173.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.21 162.02 19.09 Favored Glycine 0 C--N 1.351 1.375 0 N-CA-C 104.966 -3.253 . . . . 0.0 104.966 167.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 0.5 OUTLIER -79.59 142.36 35.73 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -178.417 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.0 p -137.77 -174.44 3.78 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 103.455 -2.795 . . . . 0.0 103.455 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -158.95 165.56 33.82 Favored 'General case' 0 N--CA 1.425 -1.679 1 N-CA-C 97.502 -4.999 . . . . 0.0 97.502 179.021 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -168.51 173.57 2.54 Favored Pre-proline 0 N--CA 1.431 -1.398 1 N-CA-C 98.831 -4.507 . . . . 0.0 98.831 -170.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -64.6 -62.25 0.03 OUTLIER 'Cis proline' 0 CA--C 1.498 -1.296 0 CA-C-N 125.753 3.09 . . . . 0.0 108.64 -1.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.346 2.8 mt 42.08 -112.87 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 C-N-CA 128.694 2.798 . . . . 0.0 112.83 177.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 60.7 mt -134.66 -146.71 0.26 Allowed 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -74.27 10.17 1.37 Allowed 'General case' 0 C--N 1.358 0.937 0 C-N-CA 124.538 1.135 . . . . 0.0 112.989 -173.383 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -70.84 -26.04 63.1 Favored 'General case' 0 C--N 1.35 0.625 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 163.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -92.99 29.59 7.91 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 176.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -117.15 104.38 11.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 176.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 89.0 m -90.81 149.62 21.9 Favored 'General case' 0 CA--C 1.483 -1.598 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 172.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -67.51 -30.15 69.75 Favored 'General case' 0 C--N 1.349 0.569 0 CA-C-N 118.626 0.648 . . . . 0.0 110.823 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.8 p -90.26 8.87 31.01 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.605 1.162 . . . . 0.0 110.194 176.012 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.17 -71.42 1.21 Allowed Glycine 0 C--N 1.351 1.401 0 O-C-N 121.162 -0.962 . . . . 0.0 111.711 167.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.6 97.9 8.73 Favored 'General case' 0 CA--C 1.504 -0.818 0 CA-C-N 117.22 0.51 . . . . 0.0 111.562 -161.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.8 t -84.94 118.87 24.8 Favored 'General case' 0 N--CA 1.439 -0.975 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 171.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 p -115.79 -132.59 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.921 1 N-CA-C 98.826 -4.509 . . . . 0.0 98.826 163.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.25 -0.41 77.45 Favored Glycine 0 C--N 1.351 1.416 0 O-C-N 118.413 -2.68 . . . . 0.0 110.949 175.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 9' ' ' PHE . 8.1 m -145.41 164.56 11.5 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.7 1 N-CA-C 100.052 -4.055 . . . . 0.0 100.052 178.403 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 91.0 m -87.57 122.72 31.63 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 170.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.68 -149.92 0.42 Allowed 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 173.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.48 155.83 40.27 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 95.924 -5.584 . . . . 0.0 95.924 170.552 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -169.62 173.08 6.53 Favored 'General case' 0 N--CA 1.423 -1.819 1 N-CA-C 95.693 -5.669 . . . . 0.0 95.693 173.804 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.89 0 O-C-N 124.203 0.94 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 . . . . . 0 N--CA 1.498 1.974 0 N-CA-C 102.552 -3.129 . . . . 0.0 102.552 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -156.47 166.31 33.79 Favored 'General case' 0 N--CA 1.428 -1.567 1 N-CA-C 95.652 -5.684 . . . . 0.0 95.652 175.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 8.5 p -168.25 177.87 5.23 Favored 'General case' 0 N--CA 1.424 -1.757 1 N-CA-C 99.354 -4.313 . . . . 0.0 99.354 -177.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.7 mt -93.56 145.62 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.358 0 N-CA-C 102.666 -3.087 . . . . 0.0 102.666 165.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -86.96 143.66 27.27 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 124.891 1.277 . . . . 0.0 107.793 -158.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 76.18 11.89 2.84 Favored 'General case' 0 CA--C 1.502 -0.869 0 C-N-CA 127.015 2.126 . . . . 0.0 111.304 -178.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -94.09 168.45 28.61 Favored Glycine 0 C--N 1.352 1.45 0 N-CA-C 105.56 -3.016 . . . . 0.0 105.56 166.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 m-85 -83.99 145.99 28.23 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -177.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 8.0 p -134.36 -157.81 0.83 Allowed 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 102.608 -3.108 . . . . 0.0 102.608 173.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.9 p -173.23 -177.13 1.47 Allowed 'General case' 0 N--CA 1.425 -1.703 1 N-CA-C 98.324 -4.695 . . . . 0.0 98.324 -179.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -160.14 165.75 17.13 Favored Pre-proline 0 N--CA 1.428 -1.558 1 N-CA-C 99.111 -4.403 . . . . 0.0 99.111 178.315 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -63.77 -65.42 0.03 OUTLIER 'Cis proline' 0 CA--C 1.503 -1.065 0 CA-C-N 125.702 3.072 . . . . 0.0 111.69 0.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -133.72 132.65 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.678 1 N-CA-C 97.024 -5.176 . . . . 0.0 97.024 167.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 20.4 mt -167.12 -96.8 0.01 OUTLIER 'General case' 0 N--CA 1.434 -1.264 1 N-CA-C 95.031 -5.914 . . . . 0.0 95.031 -179.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 mtpp -106.47 97.51 7.3 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 102.994 -2.965 . . . . 0.0 102.994 162.479 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -155.65 178.39 10.3 Favored 'General case' 0 CA--C 1.491 -1.321 1 N-CA-C 97.131 -5.137 . . . . 0.0 97.131 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.84 -84.55 0.11 Allowed Glycine 0 CA--C 1.476 -2.382 1 N-CA-C 101.757 -4.537 . . . . 0.0 101.757 175.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 99.3 mt -139.29 146.06 39.9 Favored 'General case' 0 N--CA 1.419 -1.992 1 N-CA-C 96.677 -5.305 . . . . 0.0 96.677 167.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.5 m -90.95 142.95 27.23 Favored 'General case' 0 CA--C 1.491 -1.318 0 N-CA-C 101.587 -3.486 . . . . 0.0 101.587 151.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.43 -32.69 74.45 Favored 'General case' 0 CA--C 1.505 -0.785 0 CA-C-N 119.922 1.237 . . . . 0.0 111.169 -174.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -89.67 12.23 17.5 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 124.603 1.161 . . . . 0.0 109.865 179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.17 -73.08 0.38 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 167.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -86.46 140.49 29.91 Favored 'General case' 0 CA--C 1.492 -1.264 0 O-C-N 122.129 -0.63 . . . . 0.0 110.508 -162.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.6 t -109.22 132.29 54.26 Favored 'General case' 0 CA--C 1.487 -1.452 1 N-CA-C 99.61 -4.218 . . . . 0.0 99.61 168.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.9 p -142.41 37.59 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.24 0 N-CA-C 103.346 -2.835 . . . . 0.0 103.346 177.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.68 -50.1 1.58 Allowed Glycine 0 C--N 1.351 1.385 0 N-CA-C 107.015 -2.434 . . . . 0.0 107.015 -176.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.7 m -100.28 161.79 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.19 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 162.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 36.1 m -81.07 126.23 31.17 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 170.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.62 -159.51 0.97 Allowed 'General case' 0 CA--C 1.489 -1.37 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 -173.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -145.57 155.02 42.79 Favored 'General case' 0 N--CA 1.422 -1.84 1 N-CA-C 96.297 -5.445 . . . . 0.0 96.297 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -171.52 175.82 3.96 Favored 'General case' 0 N--CA 1.424 -1.735 1 N-CA-C 96.012 -5.551 . . . . 0.0 96.012 177.493 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.944 0 O-C-N 124.231 0.957 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 . . . . . 0 N--CA 1.49 1.553 1 N-CA-C 99.669 -4.197 . . . . 0.0 99.669 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -70.48 -47.76 59.03 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 163.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.6 p -96.44 169.97 9.55 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 173.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 28.4 mt -95.33 143.89 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -69.67 144.17 52.95 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 127.314 2.245 . . . . 0.0 109.989 -162.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 81.7 m-85 66.13 27.78 10.37 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 125.857 1.663 . . . . 0.0 111.516 -171.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.6 169.67 30.29 Favored Glycine 0 C--N 1.347 1.179 0 N-CA-C 105.059 -3.216 . . . . 0.0 105.059 159.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -88.57 150.65 22.96 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 175.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.5 p -144.86 146.15 31.93 Favored 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 103.646 -2.724 . . . . 0.0 103.646 -177.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -173.68 -169.31 0.49 Allowed 'General case' 0 N--CA 1.43 -1.473 1 N-CA-C 97.571 -4.974 . . . . 0.0 97.571 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.6 pp -132.05 138.22 31.9 Favored Pre-proline 0 N--CA 1.43 -1.464 1 N-CA-C 96.456 -5.387 . . . . 0.0 96.456 155.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -59.93 167.25 21.51 Favored 'Cis proline' 0 C--N 1.324 -0.735 0 CA-C-N 122.734 2.012 . . . . 0.0 111.841 -23.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.7 tp -165.39 172.25 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 1 N-CA-C 94.711 -6.033 . . . . 0.0 94.711 178.252 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 78.2 mt -69.16 -34.25 74.69 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 119.315 0.962 . . . . 0.0 111.702 -165.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -144.22 140.01 29.03 Favored 'General case' 0 N--CA 1.43 -1.437 1 N-CA-C 97.182 -5.118 . . . . 0.0 97.182 165.255 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -103.43 154.62 19.23 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 104.977 -2.231 . . . . 0.0 104.977 -176.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 170.68 -170.11 42.87 Favored Glycine 0 N--CA 1.423 -2.203 1 N-CA-C 97.415 -6.274 . . . . 0.0 97.415 -175.15 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 21.9 tp -95.51 172.63 7.95 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 103.63 -2.73 . . . . 0.0 103.63 176.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 96.9 m -84.49 149.52 25.88 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.9 m -66.54 -39.25 88.49 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-N 118.274 0.488 . . . . 0.0 110.278 -173.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.0 p -90.15 18.36 6.02 Favored 'General case' 0 N--CA 1.439 -1.006 0 C-N-CA 124.019 0.927 . . . . 0.0 110.411 175.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.68 -70.99 1.13 Allowed Glycine 0 CA--C 1.486 -1.756 0 O-C-N 120.784 -1.198 . . . . 0.0 111.159 165.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.69 140.68 36.93 Favored 'General case' 0 CA--C 1.5 -0.97 0 CA-C-N 117.939 0.87 . . . . 0.0 109.795 -164.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.1 t -124.46 135.72 53.46 Favored 'General case' 0 CA--C 1.482 -1.668 1 N-CA-C 97.991 -4.818 . . . . 0.0 97.991 175.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.4 p -149.54 46.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.17 0 N-CA-C 103.062 -2.94 . . . . 0.0 103.062 172.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.23 -48.92 2.16 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -177.173 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.1 m -105.72 157.24 6.4 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.153 0 N-CA-C 103.641 -2.726 . . . . 0.0 103.641 164.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 85.0 m -85.23 139.62 31.5 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 172.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.43 -141.97 0.12 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 103.293 -2.854 . . . . 0.0 103.293 177.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -142.79 172.13 13.11 Favored 'General case' 0 N--CA 1.425 -1.694 1 N-CA-C 97.669 -4.938 . . . . 0.0 97.669 173.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 89.6 mt -145.43 163.2 35.38 Favored 'General case' 0 N--CA 1.421 -1.903 1 N-CA-C 94.567 -6.086 . . . . 0.0 94.567 168.051 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.873 0 O-C-N 124.13 0.894 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 . . . . . 0 N--CA 1.498 1.957 0 N-CA-C 102.32 -3.215 . . . . 0.0 102.32 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.2 m-20 75.72 -67.58 0.23 Allowed 'General case' 0 C--N 1.359 0.98 0 C-N-CA 125.57 1.548 . . . . 0.0 107.388 -164.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p -112.38 168.96 9.22 Favored 'General case' 0 N--CA 1.434 -1.233 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 172.126 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.3 mt -96.94 146.92 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 104.007 -2.59 . . . . 0.0 104.007 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.6 ttpp -76.78 139.8 40.51 Favored 'General case' 0 C--N 1.353 0.742 0 C-N-CA 125.776 1.631 . . . . 0.0 110.208 -161.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 71.05 24.11 4.02 Favored 'General case' 0 N--CA 1.443 -0.797 0 C-N-CA 126.64 1.976 . . . . 0.0 111.072 -173.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.69 167.05 14.4 Favored Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 104.101 -3.6 . . . . 0.0 104.101 165.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -75.87 152.43 37.2 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 -179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 24.7 p -150.74 171.33 17.35 Favored 'General case' 0 CA--C 1.483 -1.597 0 N-CA-C 100.623 -3.843 . . . . 0.0 100.623 169.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.9 p -167.9 179.42 4.71 Favored 'General case' 0 N--CA 1.416 -2.147 1 N-CA-C 96.502 -5.37 . . . . 0.0 96.502 175.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.96 138.92 27.21 Favored Pre-proline 0 N--CA 1.425 -1.715 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 156.821 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -62.85 163.67 47.18 Favored 'Cis proline' 0 N--CA 1.453 -0.894 0 CA-C-N 122.969 2.096 . . . . 0.0 111.048 -19.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -162.13 159.37 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.736 1 N-CA-C 95.098 -5.89 . . . . 0.0 95.098 168.549 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.7 mp -76.47 -32.99 58.71 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 123.654 0.781 . . . . 0.0 110.934 -161.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -123.17 131.33 53.64 Favored 'General case' 0 CA--C 1.485 -1.55 1 N-CA-C 97.329 -5.063 . . . . 0.0 97.329 169.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -132.14 169.67 16.07 Favored 'General case' 0 N--CA 1.431 -1.377 0 N-CA-C 100.917 -3.735 . . . . 0.0 100.917 -170.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.71 -171.63 44.58 Favored Glycine 0 N--CA 1.424 -2.124 1 N-CA-C 97.107 -6.397 . . . . 0.0 97.107 -178.126 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 70.5 mt -84.12 177.72 8.12 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 172.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.9 m -89.92 147.29 23.81 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 103.215 -2.883 . . . . 0.0 103.215 165.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 18.5 m -66.54 -36.28 82.29 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.063 0.847 . . . . 0.0 109.57 -173.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.0 p -90.19 15.43 10.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 C-N-CA 125.644 1.578 . . . . 0.0 111.498 176.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 93.88 -70.19 1.35 Allowed Glycine 0 CA--C 1.49 -1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 111.751 166.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.59 117.3 24.4 Favored 'General case' 0 CA--C 1.497 -1.065 0 O-C-N 122.413 -0.463 . . . . 0.0 111.467 -158.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 53.7 t -102.55 126.87 49.76 Favored 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 104.799 -2.297 . . . . 0.0 104.799 177.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.62 -137.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.828 1 N-CA-C 98.113 -4.773 . . . . 0.0 98.113 160.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.36 -4.55 64.68 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 117.941 -2.974 . . . . 0.0 112.097 178.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.1 m -141.88 164.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.55 1 N-CA-C 100.011 -4.07 . . . . 0.0 100.011 177.673 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 78.0 m -86.15 125.78 33.75 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 172.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.74 -146.09 0.29 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 176.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.4 p30 -153.3 -171.76 4.02 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 99.517 -4.253 . . . . 0.0 99.517 -178.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -133.61 161.49 34.49 Favored 'General case' 0 N--CA 1.426 -1.667 1 N-CA-C 94.426 -6.139 . . . . 0.0 94.426 162.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.964 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 . . . . . 0 N--CA 1.496 1.825 1 N-CA-C 98.29 -4.708 . . . . 0.0 98.29 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -93.38 -153.42 0.36 Allowed 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 101.365 -3.569 . . . . 0.0 101.365 147.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 10.5 p -104.27 -172.5 2.12 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.1 mt -89.83 140.03 16.54 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 N-CA-C 102.896 -3.001 . . . . 0.0 102.896 164.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 23.3 tptm -76.34 138.09 40.25 Favored 'General case' 0 N--CA 1.439 -0.983 0 C-N-CA 124.601 1.16 . . . . 0.0 108.246 -163.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 72.43 14.88 5.26 Favored 'General case' 0 CA--C 1.503 -0.834 0 C-N-CA 127.537 2.335 . . . . 0.0 111.492 -173.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.22 170.88 29.12 Favored Glycine 0 C--N 1.351 1.396 0 N-CA-C 105.077 -3.209 . . . . 0.0 105.077 166.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -88.47 143.71 26.81 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 -178.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -109.09 -90.91 0.45 Allowed 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 174.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.7 p -170.56 -176.02 2.01 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 100.638 -3.838 . . . . 0.0 100.638 -166.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -133.43 155.9 80.25 Favored Pre-proline 0 N--CA 1.426 -1.674 1 N-CA-C 94.935 -5.95 . . . . 0.0 94.935 170.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -62.68 166.76 36.13 Favored 'Cis proline' 0 CA--C 1.499 -1.232 0 CA-C-N 124.466 2.631 . . . . 0.0 112.718 -5.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 34.7 pt -89.83 172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.486 0 O-C-N 125.015 1.447 . . . . 0.0 107.89 -175.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 94.2 mt 111.78 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.49 -1.335 0 C-N-CA 130.509 3.523 . . . . 0.0 104.335 174.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.1 mmtm -122.07 131.57 54.05 Favored 'General case' 0 CA--C 1.482 -1.657 1 N-CA-C 96.72 -5.289 . . . . 0.0 96.72 172.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -174.73 -60.61 0.01 OUTLIER 'General case' 0 CA--C 1.486 -1.498 1 N-CA-C 98.701 -4.555 . . . . 0.0 98.701 -171.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.54 143.03 27.66 Favored Glycine 0 N--CA 1.434 -1.444 0 N-CA-C 103.643 -3.783 . . . . 0.0 103.643 159.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -104.24 95.74 6.16 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.787 -3.042 . . . . 0.0 102.787 178.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 61.7 m -90.29 154.37 19.76 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.8 m -68.56 -32.24 72.02 Favored 'General case' 0 C--N 1.355 0.827 0 CA-C-N 119.343 0.974 . . . . 0.0 110.093 178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.7 p -90.02 14.7 11.63 Favored 'General case' 0 N--CA 1.441 -0.876 0 C-N-CA 124.531 1.132 . . . . 0.0 109.685 176.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.6 -73.69 1.81 Allowed Glycine 0 CA--C 1.488 -1.655 0 O-C-N 121.003 -1.06 . . . . 0.0 111.029 168.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.51 132.14 35.21 Favored 'General case' 0 CA--C 1.496 -1.126 0 CA-C-O 121.003 0.43 . . . . 0.0 111.772 -159.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -105.53 121.94 44.99 Favored 'General case' 0 N--CA 1.436 -1.126 0 N-CA-C 102.849 -3.019 . . . . 0.0 102.849 175.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -140.73 42.85 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 104.141 -2.54 . . . . 0.0 104.141 -174.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.97 -66.27 1.6 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 -174.035 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 23.5 m -89.86 165.91 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.126 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 165.289 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 22.8 m -85.02 126.95 33.97 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 170.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.81 -146.58 0.19 Allowed 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 103.742 -2.688 . . . . 0.0 103.742 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -140.38 163.5 32.62 Favored 'General case' 0 N--CA 1.426 -1.655 1 N-CA-C 97.123 -5.14 . . . . 0.0 97.123 174.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.2 mt -149.32 163.21 38.34 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.679 -6.045 . . . . 0.0 94.679 175.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.917 0 O-C-N 124.511 1.132 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 100.91 -3.737 . . . . 0.0 100.91 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -125.78 -76.55 0.58 Allowed 'General case' 0 CA--C 1.497 -1.081 0 N-CA-C 100.775 -3.787 . . . . 0.0 100.775 175.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.6 p -124.45 174.4 7.8 Favored 'General case' 0 N--CA 1.428 -1.57 1 N-CA-C 96.998 -5.186 . . . . 0.0 96.998 158.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.441 HD11 ' HB2' ' A' ' 17' ' ' ASN . 7.6 mt -108.8 155.08 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.152 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 44.9 tttm -72.07 141.37 49.24 Favored 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 128.359 2.664 . . . . 0.0 108.336 -170.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 63.63 28.54 15.1 Favored 'General case' 0 CA--C 1.503 -0.844 0 C-N-CA 125.933 1.693 . . . . 0.0 112.996 -171.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.91 166.66 20.36 Favored Glycine 0 C--N 1.348 1.223 0 N-CA-C 104.583 -3.407 . . . . 0.0 104.583 162.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -76.76 142.53 40.36 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.733 -1.58 . . . . 0.0 106.733 176.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.0 p -123.01 166.88 14.37 Favored 'General case' 0 CA--C 1.493 -1.224 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 -178.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.2 p -150.6 158.73 44.49 Favored 'General case' 0 N--CA 1.425 -1.705 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 -164.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 70.9 mt -144.39 159.93 50.15 Favored Pre-proline 0 N--CA 1.431 -1.415 1 N-CA-C 96.263 -5.458 . . . . 0.0 96.263 178.65 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -64.77 160.66 69.56 Favored 'Cis proline' 0 CA--C 1.503 -1.064 0 CA-C-N 125.368 2.953 . . . . 0.0 110.983 -1.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 36.0 pt -88.19 137.52 20.93 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -175.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.4 mt -117.26 -68.15 0.94 Allowed 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 102.012 -3.329 . . . . 0.0 102.012 157.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -143.38 86.4 1.89 Allowed 'General case' 0 CA--C 1.487 -1.444 1 N-CA-C 99.025 -4.435 . . . . 0.0 99.025 167.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.441 ' HB2' HD11 ' A' ' 4' ' ' ILE . 10.1 p-10 178.95 -172.43 0.15 Allowed 'General case' 0 N--CA 1.43 -1.432 1 N-CA-C 97.402 -5.036 . . . . 0.0 97.402 -174.53 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.49 -62.95 4.52 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 108.13 -1.988 . . . . 0.0 108.13 -168.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 44.2 mt -69.2 117.66 11.12 Favored 'General case' 0 N--CA 1.434 -1.246 0 C-N-CA 126.303 1.841 . . . . 0.0 110.053 -171.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.3 m -90.86 153.98 19.82 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 175.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -76.53 -18.45 58.7 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-N 119.614 1.097 . . . . 0.0 110.69 -176.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.5 p -90.43 -5.19 56.4 Favored 'General case' 0 N--CA 1.435 -1.218 0 C-N-CA 123.942 0.897 . . . . 0.0 109.682 173.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.64 -87.49 0.4 Allowed Glycine 0 CA--C 1.489 -1.546 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 172.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -94.11 154.97 17.33 Favored 'General case' 0 CA--C 1.494 -1.185 0 O-C-N 122.313 -0.522 . . . . 0.0 111.503 -159.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.2 t -117.58 130.19 56.25 Favored 'General case' 0 N--CA 1.432 -1.33 0 N-CA-C 100.968 -3.715 . . . . 0.0 100.968 179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.99 45.61 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 102.111 -3.292 . . . . 0.0 102.111 176.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.25 -58.44 2.36 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 107.34 -2.304 . . . . 0.0 107.34 -178.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 m -91.57 158.48 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.134 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 161.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.6 m -80.47 139.58 36.35 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 170.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.68 -158.58 0.88 Allowed 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 104.457 -2.423 . . . . 0.0 104.457 179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -133.07 165.81 23.87 Favored 'General case' 0 N--CA 1.426 -1.664 1 N-CA-C 97.318 -5.068 . . . . 0.0 97.318 173.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.7 mt -153.45 170.69 20.11 Favored 'General case' 0 N--CA 1.422 -1.86 1 N-CA-C 95.001 -5.925 . . . . 0.0 95.001 170.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.966 0 O-C-N 124.053 0.846 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 . . . . . 0 N--CA 1.498 1.972 0 N-CA-C 102.317 -3.216 . . . . 0.0 102.317 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -162.55 -179.13 6.69 Favored 'General case' 0 N--CA 1.426 -1.657 1 N-CA-C 98.475 -4.639 . . . . 0.0 98.475 176.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 5.5 p 175.26 -175.01 0.09 Allowed 'General case' 0 N--CA 1.421 -1.879 1 N-CA-C 96.065 -5.531 . . . . 0.0 96.065 -169.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.5 mt -83.3 141.4 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.202 0 N-CA-C 104.494 -2.41 . . . . 0.0 104.494 161.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -69.23 137.92 53.56 Favored 'General case' 0 N--CA 1.44 -0.936 0 C-N-CA 125.247 1.419 . . . . 0.0 107.209 -171.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 60.75 30.75 19.9 Favored 'General case' 0 N--CA 1.44 -0.938 0 C-N-CA 127.2 2.2 . . . . 0.0 111.94 -169.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.06 171.28 13.79 Favored Glycine 0 C--N 1.35 1.354 1 N-CA-C 102.766 -4.134 . . . . 0.0 102.766 164.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -83.12 134.06 35.02 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 118.338 1.069 . . . . 0.0 111.956 -168.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -124.74 9.82 8.31 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.632 1.573 . . . . 0.0 107.145 177.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -74.52 -19.98 60.15 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.786 1.635 . . . . 0.0 109.698 -179.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 55.2 mt -137.61 150.02 66.85 Favored Pre-proline 0 N--CA 1.419 -1.988 1 N-CA-C 95.4 -5.778 . . . . 0.0 95.4 167.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -64.8 150.55 74.48 Favored 'Cis proline' 0 CA--C 1.504 -1.006 0 CA-C-N 125.066 2.845 . . . . 0.0 109.736 -10.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.9 pt -134.3 137.25 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 1 N-CA-C 98.018 -4.808 . . . . 0.0 98.018 171.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 21.1 mt -171.41 -64.4 0.02 OUTLIER 'General case' 0 CA--C 1.488 -1.411 1 N-CA-C 97.783 -4.895 . . . . 0.0 97.783 -173.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.46 -101.32 0.43 Allowed 'General case' 0 N--CA 1.426 -1.649 1 N-CA-C 93.225 -6.583 . . . . 0.0 93.225 160.719 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -157.46 171.1 20.98 Favored 'General case' 0 CA--C 1.494 -1.204 1 N-CA-C 99.377 -4.305 . . . . 0.0 99.377 166.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -110.94 142.92 17.0 Favored Glycine 0 C--N 1.356 1.684 0 N-CA-C 104.054 -3.619 . . . . 0.0 104.054 173.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 22.6 mt -93.46 141.49 28.39 Favored 'General case' 0 CA--C 1.493 -1.224 0 CA-C-O 122.561 1.172 . . . . 0.0 111.425 -161.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 56.8 m -90.34 152.28 21.09 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 126.084 1.754 . . . . 0.0 106.451 179.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 7.2 m -69.69 -31.55 69.65 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-N 118.839 0.745 . . . . 0.0 109.866 -178.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 11.6 p -85.4 -6.23 59.24 Favored 'General case' 0 N--CA 1.439 -1.013 0 C-N-CA 124.455 1.102 . . . . 0.0 111.125 179.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.09 -74.11 0.21 Allowed Glycine 0 C--N 1.349 1.261 0 O-C-N 121.56 -0.713 . . . . 0.0 112.946 170.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.75 153.0 18.55 Favored 'General case' 0 CA--C 1.492 -1.252 0 CA-C-O 121.123 0.487 . . . . 0.0 111.141 -158.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.9 t -114.58 132.97 56.16 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 -176.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.4 p -134.73 35.52 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 104.325 -2.472 . . . . 0.0 104.325 173.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.44 -47.69 1.32 Allowed Glycine 0 C--N 1.352 1.438 0 N-CA-C 106.085 -2.806 . . . . 0.0 106.085 -179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -104.3 153.64 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 N-CA-C 102.711 -3.07 . . . . 0.0 102.711 166.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 30.9 m -76.72 135.25 39.03 Favored 'General case' 0 CA--C 1.5 -0.978 0 C-N-CA 124.233 1.013 . . . . 0.0 108.844 -178.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.82 -147.4 0.22 Allowed 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -147.26 156.36 42.87 Favored 'General case' 0 N--CA 1.43 -1.466 1 N-CA-C 96.932 -5.21 . . . . 0.0 96.932 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 66.9 mt -154.99 161.29 41.42 Favored 'General case' 0 N--CA 1.428 -1.54 1 N-CA-C 94.8 -6.0 . . . . 0.0 94.8 172.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.945 0 O-C-N 124.164 0.915 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 . . . . . 0 N--CA 1.494 1.775 0 N-CA-C 105.631 -1.988 . . . . 0.0 105.631 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -166.55 -165.26 0.73 Allowed 'General case' 0 N--CA 1.434 -1.259 1 N-CA-C 96.613 -5.328 . . . . 0.0 96.613 -166.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.6 173.68 11.61 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 100.32 -3.956 . . . . 0.0 100.32 175.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.7 mt -101.26 151.1 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.283 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 174.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -82.47 144.51 30.39 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 125.353 1.461 . . . . 0.0 110.164 -159.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.292 95.2 m-85 54.0 33.51 17.66 Favored 'General case' 0 CA--C 1.5 -0.966 0 C-N-CA 127.417 2.287 . . . . 0.0 112.346 -169.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.83 170.4 34.83 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 104.202 -3.559 . . . . 0.0 104.202 158.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -81.62 149.42 28.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.9 p -147.4 170.59 17.04 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 103.43 -2.804 . . . . 0.0 103.43 176.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -179.26 178.47 0.7 Allowed 'General case' 0 N--CA 1.425 -1.715 1 N-CA-C 94.851 -5.981 . . . . 0.0 94.851 176.843 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 91.5 mt -149.74 166.42 15.27 Favored Pre-proline 0 CA--C 1.492 -1.273 1 N-CA-C 98.804 -4.517 . . . . 0.0 98.804 -171.725 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -71.24 -52.82 0.16 OUTLIER 'Cis proline' 0 CA--C 1.497 -1.365 0 CA-C-N 122.396 1.891 . . . . 0.0 109.851 -10.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.266 54.7 mt 80.63 -91.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 C-N-CA 127.979 2.512 . . . . 0.0 105.732 -175.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -144.65 175.03 10.46 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 96.142 -5.503 . . . . 0.0 96.142 175.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -78.1 74.83 4.64 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 119.061 0.846 . . . . 0.0 111.019 -170.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 74.1 m-80 -77.41 -87.61 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.212 0 C-N-CA 125.934 1.693 . . . . 0.0 106.708 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.47 -163.05 35.72 Favored Glycine 0 N--CA 1.42 -2.429 1 N-CA-C 98.414 -5.874 . . . . 0.0 98.414 174.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.4 mt -91.57 -155.15 0.39 Allowed 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 176.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.3 m -89.83 153.33 20.74 Favored 'General case' 0 CA--C 1.484 -1.584 0 N-CA-C 106.247 -1.76 . . . . 0.0 106.247 177.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -71.45 -22.23 61.85 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 29.8 p -88.7 -0.48 57.34 Favored 'General case' 0 N--CA 1.442 -0.87 0 C-N-CA 123.897 0.879 . . . . 0.0 110.583 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.95 -79.78 0.33 Allowed Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 149.57 31.1 Favored 'General case' 0 CA--C 1.499 -1.015 0 C-N-CA 123.421 0.689 . . . . 0.0 109.894 -163.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 39.2 t -140.77 148.66 41.0 Favored 'General case' 0 N--CA 1.426 -1.626 1 N-CA-C 99.369 -4.308 . . . . 0.0 99.369 -172.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.497 HG22 ' H ' ' A' ' 27' ' ' GLY . 2.4 p -159.3 -142.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.434 -1.267 1 N-CA-C 92.974 -6.676 . . . . 0.0 92.974 174.528 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.497 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -72.77 -7.03 68.63 Favored Glycine 0 C--N 1.347 1.172 0 CA-C-N 123.851 3.023 . . . . 0.0 112.176 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.5 m -135.88 153.46 32.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.38 0 N-CA-C 100.387 -3.931 . . . . 0.0 100.387 -178.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.4 m -77.27 132.18 38.53 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 166.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.06 -174.9 3.87 Favored 'General case' 0 CA--C 1.488 -1.409 0 N-CA-C 105.457 -2.053 . . . . 0.0 105.457 -173.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -154.99 173.02 17.14 Favored 'General case' 0 N--CA 1.424 -1.727 1 N-CA-C 96.579 -5.341 . . . . 0.0 96.579 173.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 84.3 mt -141.09 146.6 37.32 Favored 'General case' 0 N--CA 1.421 -1.893 1 N-CA-C 93.189 -6.596 . . . . 0.0 93.189 169.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.846 0 O-C-N 124.322 1.013 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_